Hypoplastic Left Heart Syndrome

Congenital MONDO:0004933 Pathograph 17 Show in embeddings browser congenital heart malformation univentricular heart

Underdevelopment of the entire left side of the heart, from the mitral valve through the left ventricle and aortic valve to the ascending aorta and arch, such that the left heart cannot support the systemic circulation. Two features make it unusual among congenital heart defects. The first is that its cause is genuinely unsettled, and the argument is not about which gene but about which kind of thing starts the disease. One account says an intrinsic myocardial or valvar defect comes first and the small chamber follows from it. The other says an obstruction reduces flow through the left heart in mid-gestation and the chamber fails to grow because it is not being used. Both have direct experimental support, and the most informative recent work does not choose between them so much as nest one inside the other. The second is that the treatment does not repair anything. Staged palliation rearranges the circulation so that the right ventricle pumps to the body and venous blood reaches the lungs without a pump at all. Every late problem these patients face, and there are many, belongs to the physiology of that reconstruction rather than to the original malformation. Fewer than a third are alive without a transplant at thirty-five years, and that figure has stopped improving.

Ask OpenScientist

Ask a research question about Hypoplastic Left Heart Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Inheritance
10
Pathophys.
9
Phenotypes
3
Hypotheses
3
Gaps
17
Pathograph
5
Genes
5
Medical Actions
3
Subtypes
3
Differentials
2
Models
1
Deep Research
🏷

Classifications

Harrison's Part
CARDIOVASCULAR
👪

Inheritance

2
Complex non-Mendelian inheritance HP:0001426
The dominant pattern. Family clustering establishes that this disease and related left-sided malformations are heritable, and genomic regions influencing that inheritance have been identified, yet single causal variants have not been found in most patients. The conclusion drawn in the field is not that the genetics are unknown but that the inheritance model is wrong, that expecting one disease-causing variant is the error. That is why this entry curates the genetic contribution as a distributed input to a convergent phenotype rather than as a causal gene, and why simple recurrence-risk counselling is not available.
Non-Mendelian inheritance
Show evidence (2 references)
PMID:38884762 SUPPORT Human Clinical
"However, using simple Mendelian inheritance models, identification of single genetic variants that "cause" HLHS has remained elusive, and in most cases, the genetic cause remains unknown. These results suggest that HLHS inheritance is complex rather than simple."
States the conclusion this inheritance record encodes, that the inheritance is complex rather than that the genetics are merely undiscovered.
PMID:38884762 SUPPORT Human Clinical
"Second, studies of family clustering of HLHS and related cardiovascular malformations have determined HLHS is heritable. Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
Establishes heritability and mapped contributing regions, which is what makes the absence of single causal variants informative rather than simply a gap in ascertainment.
Autosomal recessive, sarcomeric HP:0000007
A minority mechanism rather than the disease's general mode, applying to the compound heterozygous MYH6 route curated in the genetic section. It is recorded because it carries a counselling consequence the complex pattern does not, namely a defined sibling recurrence risk, and because the unaffected heterozygous parents and siblings in those families are what establish the mode.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:26085007 SUPPORT Human Clinical
"Parents and siblings who were heterozygous carriers had normal echocardiograms."
Unaffected carriers in the same families are the observation that establishes recessive rather than dominant transmission for this route. Graded PARTIAL because two families cannot establish how large a share of the disease this mode accounts for.
◆

Subtypes

3
Hypoplastic left heart syndrome with aortic atresia
The severe end of the spectrum, in which the aortic valve is imperforate. It matters mechanistically rather than only descriptively, because with no antegrade flow the ascending aorta becomes a retrograde-perfused conduit whose only function is to supply the coronary arteries. Coronary perfusion is then ductal-dependent, which is why ductal closure in this subtype threatens the myocardium and not only the systemic circulation.
Hypoplastic left heart syndrome with patent but stenotic valves
Some antegrade flow persists through hypoplastic but perforate valves. This is the subtype in which the disease can be watched developing before birth, and the subtype in which fetal intervention has been attempted, because there is a lumen to open.
Evolving hypoplastic left heart syndrome
A mid-gestation fetus with critical aortic stenosis and a left ventricle that is still of adequate size, which progresses to established hypoplasia by term if the obstruction is not relieved. It is curated as a subtype because it is the only setting in which the natural history of the disease is observable prospectively, and because it is the group in which the flow theory makes a testable prediction.
◈

Mechanistic Hypotheses

3
Flow theory, no flow no grow
flow_theory CANONICAL
Evidence balance 1 support 1 refute
An initiating obstruction at the mitral or aortic valve reduces flow through the left heart in mid-gestation, and the chamber, valves, and ascending aorta fail to grow because shear-dependent growth signalling is lost. On this account the hypoplasia is secondary and the primary lesion is mechanical. It is the model that predicts serial fetal echocardiography showing progression from isolated critical aortic stenosis to established hypoplasia, and it is the model that motivates fetal aortic valvuloplasty.
Pathograph links
Genetic lesion affecting cardiac growth or valvulogenesis -> Obstruction to left heart inflow or outflow DIRECT On the flow account the genetic lesion acts on valvulogenesis, and the mechanical consequence rather than the myocyte defect is what limits growth.
Obstruction to left heart inflow or outflow -> Reduced flow through the left heart DIRECT A stenotic or atretic valve mechanically limits the volume traversing the left heart.
Reduced flow through the left heart -> Progressive hypoplasia of left heart structures DIRECT Loss of the flow-dependent growth stimulus arrests growth of the chamber, its valves, and the ascending aorta together.
Show evidence (2 references)
PMID:42200818 SUPPORT Other
"The flow theory is strongly supported by animal models and in utero interventions that demonstrate the impact of altered hemodynamics on cardiac morphogenesis."
States both the support for the model and its two sources, animal work and the human intervention. Evidence source is OTHER because this is a review evaluating competing models rather than a primary study.
PMID:42200818 REFUTE Other
"However, the flow theory fails to identify initial causes of disturbed flow or related histological features of HLHS like endocardial fibroelastosis."
The same review's statement of what the model cannot account for, curated alongside the support so the hypothesis is recorded with its limits rather than as settled. It is a REFUTE of the model's sufficiency, not of its contribution.
Intrinsic myocardial and cell-autonomous defect
intrinsic_myocardial_defect ALTERNATIVE
Evidence balance 2 support
A primary defect of cardiomyocyte proliferation, differentiation, or sarcomeric function limits growth of the left heart directly, with the flow deficit a consequence rather than a cause. The strongest form of this argument is not that flow is irrelevant but that the flow deficit is itself downstream of a myocardial defect, which is what a myocardium-restricted genetic rescue of the structural phenotype demonstrates.
Pathograph links
Genetic lesion affecting cardiac growth or valvulogenesis -> Impaired cardiomyocyte proliferation and differentiation DIRECT On the intrinsic-defect account the genetic lesion acts first on the myocyte, limiting growth of the chamber directly.
Impaired cardiomyocyte proliferation and differentiation -> Progressive hypoplasia of left heart structures DIRECT On the strict intrinsic-defect account the small chamber follows from the cell-autonomous growth defect without requiring a flow intermediate.
Show evidence (2 references)
PMID:29569026 SUPPORT Model Organism
"Current paradigm suggests HLHS is largely of hemodynamic origin, but recent findings from analysis of the first mouse model of HLHS showed intrinsic cardiomyocyte proliferation and differentiation defects underlying the left ventricular (LV) hypoplasia."
States the challenge to the haemodynamic paradigm and its source in the first genetic mouse model of the disease.
PMID:36198703 SUPPORT Model Organism
"This work supports an emerging paradigm for HLHS pathogenesis that centers on myocardial intrinsic defects."
A second, independent model system reaching the same conclusion, which is what raises this from a single-model result to a competing account.
Myocardial defect upstream of the flow deficit
myocardial_defect_upstream_of_flow EMERGING
Evidence balance 2 support
A reconciliation rather than a third competitor. On this account an intrinsic myocardial defect impairs pump function, the impaired pump produces the flow deficit, and the flow deficit produces the structural hypoplasia, so both earlier models describe true steps in one sequence. The evidence is a genetic rescue with anatomical specificity. Restoring the gene only in myocardium rescues the ventricular, valve, and aortic phenotypes together, which is what one expects if all three are downstream of pump function and not if they are independent lesions. This is recorded as EMERGING because it rests on one model organism.
Recorded as a distinct hypothesis rather than folded into either parent because it makes a different prediction from both. The flow theory predicts that relieving obstruction should rescue growth regardless of myocardial genotype, and the intrinsic-defect model predicts that relieving obstruction should not help. This one predicts that relief should help partially and variably, depending on how much of the pump deficit is mechanical, which is closer to what fetal aortic valvuloplasty actually achieves.
Pathograph links
Genetic lesion affecting cardiac growth or valvulogenesis -> Impaired cardiomyocyte proliferation and differentiation DIRECT On the intrinsic-defect account the genetic lesion acts first on the myocyte, limiting growth of the chamber directly.
Impaired cardiomyocyte proliferation and differentiation -> Reduced flow through the left heart DIRECT A myocardium that cannot pump adequately generates less flow, which is the reconciliation the tissue-restricted rescue experiment supports.
Reduced flow through the left heart -> Progressive hypoplasia of left heart structures DIRECT Loss of the flow-dependent growth stimulus arrests growth of the chamber, its valves, and the ascending aorta together.
Show evidence (2 references)
PMID:36198703 SUPPORT Model Organism
"In contrast to current models, we demonstrate that these structural deficits arise secondary to impaired pump function as these phenotypes are rescued when Rbfox is specifically expressed in the myocardium."
The tissue-restricted rescue is what makes this more than a correlation. It places the myocardial defect upstream of the structural deficits while leaving the flow-dependence of those deficits intact.
PMID:36198703 SUPPORT Model Organism
"Here, we report that zebrafish lacking two orthologs of the RNA binding protein RBFOX2, a gene linked to HLHS in humans, display cardiovascular defects overlapping those in HLHS patients including ventricular, valve, and aortic deficiencies."
Establishes what the model reproduces. Graded PARTIAL because a zebrafish, which has a two-chambered heart and no left ventricle in the mammalian sense, can model the mechanism without modelling the anatomy.
?

Discussions and Knowledge Gaps

3
Does hypoplastic left heart syndrome begin with a myocardial defect, with a valvar obstruction, or with something that produces both?
CONTROVERSY OPEN what_starts_the_disease
Attached to
pathophysiology#Reduced flow through the left heart pathophysiology#Impaired cardiomyocyte proliferation and differentiation
This is the field's central unsettled question and it is unusual in being a dispute about the kind of cause rather than the identity of one. The flow theory has the strongest human support, since relieving an obstruction in mid-gestation lets left-sided structures grow. The intrinsic-defect account has the strongest cellular support, since the first genetic mouse model showed proliferation and differentiation defects and a second, independent model in a different organism agreed. The reconciling position, that a myocardial defect impairs pump function and the resulting flow deficit produces the structural lesion, is supported by a tissue-restricted rescue but rests on one model organism with a heart that has no left ventricle. The practical stake is which fetuses can be helped, since only the mechanical component is currently addressable.
Proposed experiments
Genotype-stratified analysis of fetal valvuloplasty response
exp_genotype_stratified_fetal_intervention
Sequence a cohort undergoing fetal aortic valvuloplasty and test whether achieving a biventricular circulation is predicted by the absence of variants in myocardial growth and sarcomeric genes. The three hypotheses make different predictions. Pure flow theory predicts no genotype effect, the intrinsic-defect model predicts poor response regardless, and the reconciling model predicts response is graded by how much of the pump deficit is mechanical.
Show evidence (1 reference)
PMID:42200818 SUPPORT Other
"No single hypothesis has fully explained how HLHS is initiated, progresses, and presents with the clinical conditions that are encountered by cardiac surgeons and cardiologists."
The review's own verdict, which is the reason this entry curates three hypothesis groups rather than selecting one. Evidence source is OTHER because it is a review.
Is failure of the systemic right ventricle after palliation an afterload consequence, an expression of the same myocardial defect that arrested the left ventricle, or both?
KNOWLEDGE GAP OPEN is_late_right_ventricular_failure_a_myopathy
Attached to
pathophysiology#Systemic right ventricle after staged palliation
The default assumption is mechanical, that a chamber built for low pressure eventually fails under systemic load. Two independent observations complicate it. Patients with this disease fare substantially worse after Fontan palliation than patients with other anatomies who have the same systemic right ventricle and the same operation, which points at something in the disease rather than in the load. And recessive sarcomeric variants were found in patients who developed late right ventricular dysfunction, with the authors framing it as one molecular basis expressed as developmental arrest on the left and latent myopathy on the right. If that is general, then some patients are destined to fail regardless of haemodynamic optimisation, and identifying them prospectively would change transplant listing rather than only prognosis.
Proposed experiments
Sarcomeric genotype and systemic right ventricular trajectory
exp_sarcomeric_genotype_and_fontan_rv_function
In a multicentre Fontan cohort, test whether rare sarcomeric and cardiomyopathy-gene variant burden predicts the rate of decline in systemic right ventricular ejection fraction independently of haemodynamic variables, using other single-ventricle anatomies as the comparator group.
Show evidence (2 references)
PMID:39604028 SUPPORT Human Clinical
"The composite outcome occurred in 7.1 versus 2.1 cases per 100 person-years in patients with HLHS versus non-HLHS (P<0.0001)."
Isolates the disease from the operation and the ventricular morphology by comparing against other single-ventricle anatomies, which is what makes the excess risk informative about intrinsic myocardium.
PMID:26085007 SUPPORT Human Clinical
"These findings implicate a shared molecular basis for the developmental arrest and latent myopathy of left and right ventricles, respectively."
States the hypothesis in the authors' own terms. Graded PARTIAL because it rests on two patients and cannot establish how much of the population-level excess risk it explains.
Can a disease defined by the failure of one specific chamber to grow be modelled in organisms whose hearts are not built the same way?
HUMAN MODEL MISMATCH OPEN model_systems_lack_a_left_ventricle
Attached to
pathophysiology#Impaired cardiomyocyte proliferation and differentiation pathophysiology#Reduced flow through the left heart
The two model systems that carry most of the mechanistic weight in this entry both have an anatomical mismatch with the disease. The zebrafish heart has a single ventricle and no left heart in the mammalian sense, so a model of RBFOX2 loss can show that structural deficits are downstream of pump function without showing that the human left ventricle behaves the same way. The mouse has the right anatomy but reaches the phenotype through mutations that are not the ones most human patients carry, and the human genetic architecture includes lower-penetrance and common variation that single-locus mouse lines do not represent. This is a fidelity question rather than an absence of evidence, since the experiments themselves are strong. What is uncertain is how far a conclusion about causal order in a two-chambered heart transfers to a four-chambered one.
Proposed experiments
Flow manipulation in patient-derived human cardiac organoids
exp_human_cardiac_organoid_flow_manipulation
Use patient-derived induced pluripotent stem cell cardiac organoids or chamber-forming cardioids carrying HLHS-associated variants, with controlled perfusion, to test whether the growth deficit is cell-autonomous, flow-dependent, or both in human tissue with human genetic background, closing the anatomical and genetic gaps the animal models leave open.
Show evidence (2 references)
PMID:36198703 SUPPORT Model Organism
"Here, we report that zebrafish lacking two orthologs of the RNA binding protein RBFOX2, a gene linked to HLHS in humans, display cardiovascular defects overlapping those in HLHS patients including ventricular, valve, and aortic deficiencies."
The word overlapping is doing the work. The defects correspond rather than being identical, which is the mismatch this discussion is about. Graded PARTIAL for that reason.
PMID:36286267 SUPPORT Human Clinical
"However, unlike classical Mendelian disorders where a relatively small number of genes are largely determinative of the occurrence and severity of the disease, the picture in HLHS is complex."
Supports the second half of the mismatch, that the human genetic architecture is not the single-locus architecture the mouse lines instantiate.
⚙

Pathophysiology

10
Genetic lesion affecting cardiac growth or valvulogenesis
Variants in cardiac transcription factors, signalling genes, sarcomeric genes, and chromatin regulators contribute to the disease, but not in the way a Mendelian disorder does. Eight independent mouse lines produce the phenotype, the human genetic architecture combines de novo single-gene and copy-number lesions with lower-penetrance and common variation, and no single gene accounts for more than a small fraction of cases. That architecture is itself a mechanistic claim, because it says the phenotype is a convergence point reachable by many routes rather than the readout of one pathway.
Flow theory, no flow no grow Intrinsic myocardial and cell-autonomous defect Myocardial defect upstream of the flow deficit
cardiac ventricle development GO:0003231 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cardiac ventricle development (GO:0003231). GO:0003231 is a biological process from the Gene Ontology. ↓ DECREASED heart valve development GO:0003170 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased heart valve development (GO:0003170). GO:0003170 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
Genetic mouse models of hypoplastic left heart OTHER Eight independent lines establish the multigenic architecture the trigger node describes.
Downstream
Impaired cardiomyocyte proliferation and differentiation On the intrinsic-defect account the genetic lesion acts first on the myocyte, limiting growth of the chamber directly. Intrinsic myocardial and cell-autonomous defect Myocardial defect upstream of the flow deficit
Obstruction to left heart inflow or outflow On the flow account the genetic lesion acts on valvulogenesis, and the mechanical consequence rather than the myocyte defect is what limits growth. Flow theory, no flow no grow
Show evidence (2 references)
PMID:36286267 SUPPORT Human Clinical
"De novo single-gene and copy number variant (CNV) disorders make an important contribution, but there is emerging evidence for causal contributions from lower penetrance and common variation."
States the mixed architecture, which is the basis for modelling the genetic contribution as a distributed input to a convergent phenotype rather than as a causal gene.
PMID:29569026 SUPPORT Model Organism
"Analysis of 8 independent HLHS mouse lines showed HLHS is genetically heterogeneous and multigenic in etiology."
Supports genetic heterogeneity from the model-organism side, independently of the human sequencing data.
Impaired cardiomyocyte proliferation and differentiation
Cardiomyocytes in the developing left ventricle proliferate less and differentiate abnormally, with disorganised sarcomeric architecture and altered mitochondrial maturation. This is what the first genetic mouse model of the disease showed, and it is the node that distinguishes an intrinsically small ventricle from a ventricle that is small because it is unused.
Intrinsic myocardial and cell-autonomous defect Myocardial defect upstream of the flow deficit
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Rbfox-deficient zebrafish OTHER The model localises the primary defect to the myocardium by tissue-restricted rescue.
Genetic mouse models of hypoplastic left heart OTHER The models demonstrate cell-autonomous proliferation and differentiation defects underlying the hypoplasia.
Downstream
Reduced flow through the left heart A myocardium that cannot pump adequately generates less flow, which is the reconciliation the tissue-restricted rescue experiment supports. Myocardial defect upstream of the flow deficit
Progressive hypoplasia of left heart structures On the strict intrinsic-defect account the small chamber follows from the cell-autonomous growth defect without requiring a flow intermediate. Intrinsic myocardial and cell-autonomous defect
Show evidence (1 reference)
PMID:29569026 SUPPORT Model Organism
"Current paradigm suggests HLHS is largely of hemodynamic origin, but recent findings from analysis of the first mouse model of HLHS showed intrinsic cardiomyocyte proliferation and differentiation defects underlying the left ventricular (LV) hypoplasia."
Directly supports impaired proliferation and differentiation as the cellular lesion beneath the hypoplasia in a genetic model.
Obstruction to left heart inflow or outflow
Stenosis or atresia of the mitral or aortic valve. In the evolving form this is present in mid-gestation while the left ventricle is still of adequate size, so the obstruction can be observed before the hypoplasia it is proposed to cause.
Flow theory, no flow no grow
aortic valve UBERON:0002137 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in aortic valve (UBERON:0002137). UBERON:0002137 is an anatomical location from the Uberon multi-species anatomy ontology. mitral valve UBERON:0002135 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in mitral valve (UBERON:0002135). UBERON:0002135 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Reduced flow through the left heart A stenotic or atretic valve mechanically limits the volume traversing the left heart. Flow theory, no flow no grow
Reduced flow through the left heart
Whatever puts it there, reduced flow across the mitral valve and out through the aortic valve is the shared middle of the disease. The claim attached to it is that flow is not merely a consequence of chamber size but an input to chamber growth, so that a left heart carrying less volume grows less. That claim is testable in humans, and it has been tested.
Flow theory, no flow no grow Myocardial defect upstream of the flow deficit
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Rbfox-deficient zebrafish OTHER It places the flow deficit downstream of impaired pump function rather than upstream of the myocardial phenotype.
Downstream
Progressive hypoplasia of left heart structures Loss of the flow-dependent growth stimulus arrests growth of the chamber, its valves, and the ascending aorta together. Flow theory, no flow no grow Myocardial defect upstream of the flow deficit
Endocardial fibroelastosis Abnormal endocardial shear is associated with a fibroelastic lining of the ventricular cavity, though the flow account does not by itself explain this lesion.
Endocardial fibroelastosis
A layer of fibroelastic tissue lining the hypoplastic ventricular cavity, further reducing compliance and inflow. It is curated as its own node because it is the specific finding the flow theory is criticised for failing to explain, so collapsing it into the hypoplasia node would hide the weakness in the model.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology. endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Progressive hypoplasia of left heart structures A non-compliant cavity lining further restricts filling and therefore further restricts the volume available to drive growth.
Show evidence (1 reference)
PMID:42200818 SUPPORT Other
"However, the flow theory fails to identify initial causes of disturbed flow or related histological features of HLHS like endocardial fibroelastosis."
Identifies endocardial fibroelastosis as a histological feature the dominant model does not account for, which is why this entry gives it a node rather than treating it as detail. Evidence source is OTHER because this is a review.
Progressive hypoplasia of left heart structures
By term the mitral valve, left ventricle, aortic valve, and ascending aorta and arch are all markedly undersized or atretic. The word progressive is doing real work here. This is not a malformation fixed at the moment of organogenesis but one that develops across gestation, which is precisely why a mid-gestation intervention is conceivable at all.
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology. ascending aorta UBERON:0001496 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ascending aorta (UBERON:0001496). UBERON:0001496 is an anatomical location from the Uberon multi-species anatomy ontology. arch of aorta UBERON:0001508 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in arch of aorta (UBERON:0001508). UBERON:0001508 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Ductus-dependent systemic and coronary perfusion A left heart that cannot eject to the body leaves the systemic circulation dependent on right-to-left flow through the arterial duct.
Restrictive or intact atrial septum Because a hypoplastic or atretic mitral valve gives the left atrium no forward outlet, the adequacy of the interatrial communication becomes the sole determinant of whether pulmonary venous return can escape.
Restrictive or intact atrial septum
The left atrium in this disease receives the entire pulmonary venous return and has no outlet through a hypoplastic or atretic mitral valve, so that blood can only leave across the atrial septum. When the interatrial communication is small or absent the pulmonary veins are obstructed in utero, and the consequence is not merely haemodynamic. Sustained pulmonary venous hypertension remodels the lung itself, producing pulmonary lymphangiectasia, so the child is born with lung disease as well as heart disease. This is why an intact septum converts an operable malformation into an emergency at the moment of delivery, and why it is the single prenatal finding that most changes prognosis.
lung UBERON:0002048 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in lung (UBERON:0002048). UBERON:0002048 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Circulatory collapse on ductal closure An obstructed interatrial communication compounds the postnatal emergency, since pulmonary venous return cannot reach the systemic circulation even while the duct remains open.
Show evidence (2 references)
PMID:41185129 SUPPORT Human Clinical
"Fetuses with hypoplastic left heart syndrome (HLHS) and restrictive/intact atrial septum (RAS) have high mortality, partly due to pulmonary lymphangiectasia (PL)."
States both the prognostic weight of the finding and the mechanism by which it kills, which is lung remodelling rather than the cardiac lesion alone.
PMID:41185129 SUPPORT Human Clinical
"Most had a hypoplastic left atrium (LA, 80%). Four atrial septal morphology patterns were identified. PL was present among all patterns and associated with lower VTI ratio (p = 0.046)."
Links the degree of obstruction, measured as the pulmonary venous flow ratio, to the lung lesion, which is what makes this a graded mechanism rather than a binary anatomical finding.
Ductus-dependent systemic and coronary perfusion
After birth the entire systemic output crosses the arterial duct from the pulmonary artery, and the right ventricle supplies both circulations in parallel. In aortic atresia the ascending aorta carries only retrograde flow to the coronary arteries, so the coronary supply is ductal-dependent too. Systemic and pulmonary flow now compete for the same output, which is why a fall in pulmonary vascular resistance after birth paradoxically worsens systemic perfusion by stealing flow into the lungs.
ascending aorta UBERON:0001496 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ascending aorta (UBERON:0001496). UBERON:0001496 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Circulatory collapse on ductal closure Closure of the duct removes the only route by which blood reaches the body and, in aortic atresia, the heart itself.
Circulatory collapse on ductal closure
The duct closes over the first days of life and systemic perfusion fails, producing shock, acidosis, and death. This is the reason the disease is uniformly fatal untreated and the reason prostaglandin infusion is the first intervention, since keeping the duct open buys the time in which everything else becomes possible.
Downstream
Systemic right ventricle after staged palliation Surgical palliation prevents the collapse and substitutes a reconstructed circulation, which is the state the patient then lives in.
Systemic right ventricle after staged palliation
The reconstruction leaves the right ventricle pumping to the body and, after the final stage, venous blood flowing to the lungs without a ventricle behind it. This is not a repair and the entry curates it as a disease state rather than as an outcome. The right ventricle is not built for systemic afterload and eventually fails in a substantial proportion. There is also evidence that this failure is not purely mechanical wear, since recessive sarcomeric variants found in patients who developed late right ventricular dysfunction suggest the same molecular defect that arrested the left ventricle can express itself later as a myopathy of the right. Patients with this disease do worse after the same operation than patients with other single-ventricle anatomies, which is consistent with something intrinsic to the myocardium rather than to the plumbing.
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
heart right ventricle UBERON:0002080 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart right ventricle (UBERON:0002080). UBERON:0002080 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:26085007 SUPPORT Human Clinical
"These findings implicate a shared molecular basis for the developmental arrest and latent myopathy of left and right ventricles, respectively."
The specific claim this node makes, that late right ventricular failure may be a delayed expression of the same molecular lesion rather than only the cost of systemic afterload.
PMID:39604028 SUPPORT Human Clinical
"In multivariable analyses, HLHS was associated with a significantly higher risk of the composite outcome"
Compares this disease against other anatomies palliated the same way and with the same systemic right ventricle, so the excess risk is attributable to something in the disease rather than to the operation. This is the epidemiological counterpart of the genetic argument above.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hypoplastic Left Heart Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 2
Patent ductus arteriosus HP:0001643 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Patent ductus arteriosus (HP:0001643). HP:0001643 is a phenotype from the Human Phenotype Ontology.
Coarctation of the aorta Coarctation of aorta HP:0001680 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Coarctation of aorta (HP:0001680). HP:0001680 is a phenotype from the Human Phenotype Ontology.
Integument 1
Cyanosis HP:0000961 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cyanosis (HP:0000961). HP:0000961 is a phenotype from the Human Phenotype Ontology.
Other 6
Hypoplastic left ventricle HP:0004383 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypoplastic left ventricle (HP:0004383), qualified as course progressive. HP:0004383 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Aortic valve atresia HP:0010883 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic valve atresia (HP:0010883). HP:0010883 is a phenotype from the Human Phenotype Ontology.
Mitral atresia HP:0011560 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral atresia (HP:0011560). HP:0011560 is a phenotype from the Human Phenotype Ontology.
Endocardial fibroelastosis HP:0001706 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Endocardial fibroelastosis (HP:0001706). HP:0001706 is a phenotype from the Human Phenotype Ontology.
Cardiogenic shock on ductal closure HP:0030149 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cardiogenic shock (HP:0030149), qualified as temporality acute; severity severe. HP:0030149 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE Severity: SEVERE
Right ventricular failure after palliation HP:0001708 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Right ventricular failure (HP:0001708), qualified as course progressive. HP:0001708 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:26085007 SUPPORT Human Clinical
"Evaluation of cardiac structure and function by echocardiography in patients with hypoplastic left heart and their first-degree relatives identified 5 individuals with right ventricular ejection fraction ≤40% after Fontan operation."
Documents the phenotype in a Fontan-palliated cohort with an explicit functional threshold.
🧬

Genetic Associations

5
MYH6
Gene: MYH6 hgnc:7576 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MYH6 (hgnc:7576). hgnc:7576 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (3 references)
PMID:33325730 SUPPORT Human Clinical
"rare variant burden testing of 56 genes revealed enrichment in MYH6 (P=0.000068)"
Provides the case-control burden evidence, which is stronger than the family-based findings alone.
PMID:26085007 SUPPORT Human Clinical
"Secondary family-based filtering for de novo and recessive variants revealed rare inherited missense mutations on both paternal and maternal alleles of MYH6, encoding myosin heavy chain 6, in 2 patients who developed right ventricular dysfunction 3 to 11 years postoperatively."
Establishes the recessive mode and its association with the late right ventricular phenotype, which is the specific claim the systemic right ventricle node depends on.
PMID:26085007 SUPPORT Human Clinical
"Parents and siblings who were heterozygous carriers had normal echocardiograms."
Supports recessive inheritance for this mechanism by showing carriers are unaffected. Graded PARTIAL because the number of families is very small.
NOTCH1
Gene: NOTCH1 hgnc:7881 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NOTCH1 (hgnc:7881). hgnc:7881 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:38884762 SUPPORT Human Clinical
"Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
Supports the existence of mapped genomic contributions, which is the category this gene belongs to. Graded PARTIAL because it does not name this locus and therefore cannot establish its individual contribution.
NKX2-5
Gene: NKX2-5 hgnc:2488 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NKX2-5 (hgnc:2488). hgnc:2488 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:38884762 SUPPORT Human Clinical
"Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
As for NOTCH1, this supports the category rather than the locus. Graded PARTIAL for the same reason, and the two genes are curated at the same evidential strength deliberately, since neither has cohort-frequency evidence cited here.
Cytogenetic abnormality
Gene: chromosomal abnormality associated with hypoplastic left heart syndrome Relation: this disease-associated gene is this gene This disease-associated gene is chromosomal abnormality associated with hypoplastic left heart syndrome. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:38884762 SUPPORT Human Clinical
"First, some HLHS cases have been associated with cytogenetic abnormalities (e.g., Turner syndrome)."
Establishes the cytogenetic association and names the recurrent example, which is the whole of the claim this record makes.
RBFOX2
Gene: RBFOX2 hgnc:9906 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is RBFOX2 (hgnc:9906). hgnc:9906 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY variant_origin: GERMLINE
Show evidence (1 reference)
PMID:36198703 SUPPORT Model Organism
"Injection of human RBFOX2 mRNA restores cardiovascular development in rbfox mutant zebrafish, while HLHS-linked RBFOX2 variants fail to rescue."
Functional evidence that the human variants are loss of function, since wild-type human messenger RNA rescues and the patient variants do not. Graded PARTIAL because the assay is cross-species complementation rather than a human genetic association.
💊

Medical Actions

5
Prostaglandin E1 infusion
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: prostaglandin E1 CHEBI:15544 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses prostaglandin E1 (CHEBI:15544). CHEBI:15544 is a therapeutic agent from Chemical Entities of Biological Interest.
Maintains ductal patency from birth until surgery. It does nothing to the malformation and is not a treatment of the disease in any mechanistic sense, but without it the patient dies of the next node in the chain within days.
Mechanism Target:
INHIBITS Circulatory collapse on ductal closure — Preventing ductal closure preserves the only route by which blood reaches the systemic and, in aortic atresia, the coronary circulation.
Show evidence (1 reference)
PMID:40390868 SUPPORT Human Clinical
"Prostaglandin E1 (PGE1) is used to maintain the ductus arteriosus open in neonates with ductal-dependent heart lesions but is associated with apnea."
States both the indication this treatment is curated for and its principal toxicity in the same sentence. Apnoea matters practically, since it is the reason these neonates are often intubated for transport rather than for their cardiac lesion.
Balloon atrial septostomy
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
Catheter enlargement of the interatrial communication, performed urgently after birth when the septum is restrictive or intact, and increasingly attempted before birth. It is the direct counterpart of the restrictive-septum emergency, and the fetal version is the second intervention in this disease that acts on mechanism rather than consequence. Fetal atrial septal intervention improves the measured degree of pulmonary venous obstruction, and in some fetuses the associated lung lesion improves too. Whether that translates into survival is not established, since mortality in the reported series did not differ by whether intervention was performed.
Mechanism Target:
INHIBITS Restrictive or intact atrial septum — Enlarging the interatrial communication relieves the obstruction to pulmonary venous egress, which is the lesion driving the lung disease.
Show evidence (2 references)
PMID:41185129 SUPPORT Human Clinical
"Mean VTI ratio improved in fetuses who underwent atrial septal intervention (n = 12), compared to those without (p = 0.001)."
Establishes that the intervention relieves the physiological obstruction it targets, which is the mechanistic claim rather than the outcome claim.
PMID:41185129 SUPPORT INDIRECT Human Clinical
"Seventeen neonates were live-born with intention-to-treat; 6-months mortality was 38% with no difference by morphology pattern, PL, or fetal intervention."
Bounds the claim deliberately. The physiological target improves while mortality does not differ, so this entry curates the intervention as mechanism-directed without asserting survival benefit. Graded INDIRECT for that reason.
Staged single-ventricle palliation
Action: Surgical ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. NCIT:C15329
Three operations converting a parallel, ductal-dependent circulation into a series circulation with the right ventricle as the systemic pump and passive venous return to the lungs. It is the reason the disease is survivable and it is also the origin of the disease these patients live with afterwards. In the largest long-term cohort fewer than a third were alive without transplantation at thirty-five years, and survival has not improved in recent eras, which is a statement about the limits of the approach rather than about surgical technique.
Mechanism Target:
INHIBITS Ductus-dependent systemic and coronary perfusion — Reconstruction gives the right ventricle a permanent unobstructed path to the aorta, removing the dependence on the duct.
Show evidence (1 reference)
PMID:40533128 SUPPORT Human Clinical
"Transplant-free survival was 31.0% at 35 years. Transplant-free survival improved over time but is not different across recent eras."
Quantifies both the survival achieved and the plateau. Graded PARTIAL because it supports the operation as life-prolonging while simultaneously bounding what it achieves, which is the balanced claim this entry makes.
Fetal aortic valvuloplasty
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
Catheter dilation of a stenotic aortic valve in mid-gestation, attempted in fetuses with critical aortic stenosis whose left ventricle has not yet become hypoplastic. It is the only treatment in this disease that acts on mechanism rather than on consequence, and it is simultaneously the strongest human test of the flow theory, since it predicts that relieving obstruction should permit left heart growth. It partly does. Just over forty percent of live-born fetuses in the largest series achieved a biventricular circulation, and their left-sided structures were significantly larger at birth. Most still required postnatal intervention, so the result supports flow-dependent growth without supporting a cure.
Mechanism Target:
INHIBITS Obstruction to left heart inflow or outflow — Dilating the stenotic valve restores antegrade flow through the left heart during the gestational window in which the chamber is still growing.
Show evidence (3 references)
PMID:25052401 SUPPORT Human Clinical
"Eighty-eight fetuses were live-born, and 38 had a BV circulation (31 from birth, 7 converted after initial univentricular palliation)."
Quantifies how often the intervention achieved a two-ventricle circulation, which is the outcome the flow theory predicts should be attainable.
PMID:25052401 SUPPORT Human Clinical
"Left-sided structures, namely aortic and mitral valve sizes and left ventricular volume, were significantly larger in the BV group at the time of birth (P<0.01)."
This is the mechanistic result rather than the clinical one. Structures downstream of the relieved obstruction were larger, which is the growth response the flow theory posits.
PMID:25052401 SUPPORT Human Clinical
"All but 1 of the BV patients required postnatal intervention; 42% underwent aortic or mitral valve replacement."
Bounds the claim. A biventricular circulation is not a normal heart, and curating this alongside the successes keeps the entry from overstating what relieving the obstruction achieves. Graded PARTIAL for that reason.
Cardiac transplantation
Action: Organ TransplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Organ Transplantation (NCIT:C15289). NCIT:C15289 is a clinical intervention from the NCI Thesaurus. NCIT:C15289
Replacement of the heart, used when the systemic right ventricle fails or when palliation is not feasible. It is the only treatment that removes the underlying myocardium, which matters if the late failure is partly a myopathy rather than only afterload mismatch, and it is limited by donor availability in the relevant age group.
Mechanism Target:
INHIBITS Systemic right ventricle after staged palliation — Transplantation replaces the failing systemic ventricle and, with it, any intrinsic myocardial defect it carried.
🔬

Diagnosis

4
Fetal echocardiography
Prenatal diagnosis, which for this disease is not simply earlier diagnosis but a different clinical situation. It permits delivery at a surgical centre with prostaglandin ready, and in the evolving form it permits serial assessment and the possibility of fetal intervention.
Newborn pulse oximetry screening
Detection of the ductal-dependent circulation before collapse by measuring saturation in a well infant. It works here because the mixing lesion produces measurable desaturation before it produces symptoms, and it is the intervention that most changes whether a child presents electively or in shock.
Postnatal echocardiography
Confirms the anatomy and, critically, the adequacy of the interatrial communication, since a restrictive atrial septum obstructs pulmonary venous return and constitutes an emergency separate from the ductal one.
Genetic and cytogenetic testing
Chromosomal analysis and sequencing, offered because a minority of cases occur within a cytogenetic syndrome and because family clustering establishes heritability. What testing can deliver here is bounded in an unusual way. It reliably identifies the syndromic minority, and it usually does not identify a causal variant in the rest, not because the sequencing is inadequate but because the inheritance is not the kind a single variant explains. Counselling therefore has to distinguish a syndromic diagnosis, which carries its own recurrence risk and extracardiac surveillance, from a negative result, which does not mean the disease is non-genetic.
Show evidence (1 reference)
PMID:38884762 SUPPORT Human Clinical
"The implication of this conclusion is that researchers must move beyond the expectation that a single disease-causing variant can be found."
Supports the limitation this diagnostic entry records, that a negative sequencing result is the expected outcome rather than an informative exclusion.
📈

Progression

5
Mid-gestation
In the evolving form, critical aortic stenosis is present while the left ventricle is still of adequate size. This is the only window in which the disease can be modified rather than palliated.
Term
Left heart structures are established as hypoplastic or atretic and the circulation is committed to ductal dependence.
First days of life
The duct closes and systemic perfusion fails without prostaglandin. This is the point at which the disease was uniformly fatal before surgical palliation.
Staged palliation through childhood
Three operations over the first few years convert the parallel circulation to a series circulation with a systemic right ventricle and passive pulmonary flow.
Adult survivorship
Fewer than a third are alive without transplantation at thirty-five years, and the figure has not improved across recent surgical eras. Outcome is heterogeneous, with a subset reporting good to excellent health.
Show evidence (1 reference)
PMID:40533128 SUPPORT Human Clinical
"In this cohort of newborns undergoing staged reconstructive surgery for HLHS, fewer than one-third are alive without a transplant at 35 years of age. Survival has not improved in recent years."
Supports both the long-term survival figure and the plateau, in a cohort of over two thousand neonates spanning four decades.
📊

Prevalence

1
Newborns with congenital heart disease
Unknown Unknown
An estimated three percent of newborns with congenital heart disease develop this condition. That is a proportion of a diseased population rather than a population rate, so it is recorded in notes with its own evidence rather than normalised into a rate per hundred thousand, which would misrepresent the denominator.
Show evidence (1 reference)
PMID:40386366 SUPPORT Human Clinical
"An estimated 3% of all newborns with congenital heart disease develop hypoplastic left heart syndrome (HLHS), making it a prominent cause of mortality in this group if surgical procedures or a heart transplant are not implemented."
Gives the proportion among newborns with congenital heart disease, which is the denominator this record uses.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Hypoplastic Left Heart Syndrome:

Critical aortic stenosis with an adequate left ventricle
Overlapping Features The distinction that matters most before birth, because it separates a fetus who might be offered valvuloplasty and a biventricular outcome from one already committed to single ventricle palliation. It is a judgement about a spectrum rather than a categorical difference, which is why the evolving form is curated as a subtype here.
Other functionally univentricular hearts
Overlapping Features Tricuspid atresia, double inlet left ventricle, and unbalanced atrioventricular septal defect all end in the same Fontan pathway. They are worth distinguishing because outcomes differ, and this disease does worse than the others despite the same operation and the same systemic right ventricle.
Neonatal sepsis
Overlapping Features Shares shock, acidosis, and poor perfusion in a previously well newborn, and is the diagnosis usually reached first in an infant who collapses on ductal closure without a prenatal diagnosis. Fluid resuscitation and antibiotics do not help, and the delay is consequential.
🧫

Experimental Models

2
Rbfox-deficient zebrafish OTHER
Zebrafish lacking both orthologues of RBFOX2, which develop ventricular, valve, and aortic deficiencies overlapping the human phenotype. Its importance is not that it phenocopies the disease but that it can be dissected. Restoring the gene only in myocardium rescues the structural phenotypes, which places the myocardial defect upstream of the flow deficit and upstream of the structural lesions, and human wild-type messenger RNA rescues while patient-derived variants do not, which establishes those variants as loss of function. Its limitation is anatomical, since the zebrafish heart has one ventricle and no left heart in the mammalian sense, so the model can support the mechanism without supporting the anatomy.
Organism
zebrafish NCBITaxon:7955 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in zebrafish, annotated with Danio rerio (NCBITaxon:7955). NCBITaxon:7955 is an organism from the NCBI Taxonomy.
Publication
PMID:36198703
Pathograph links
Impaired cardiomyocyte proliferation and differentiation The model localises the primary defect to the myocardium by tissue-restricted rescue.
Reduced flow through the left heart It places the flow deficit downstream of impaired pump function rather than upstream of the myocardial phenotype.
Show evidence (2 references)
PMID:36198703 SUPPORT Model Organism
"In contrast to current models, we demonstrate that these structural deficits arise secondary to impaired pump function as these phenotypes are rescued when Rbfox is specifically expressed in the myocardium."
The tissue-restricted rescue, which is the experiment that makes this model informative about causal order rather than only about phenotype.
PMID:36198703 SUPPORT Model Organism
"Mechanistically, we find diminished expression and alternative splicing of sarcomere and mitochondrial components that compromise sarcomere assembly and mitochondrial respiration, respectively."
Identifies the molecular consequence, which connects a splicing regulator to the contractile and energetic machinery a pump depends on.
Genetic mouse models of hypoplastic left heart OTHER
A panel of independently derived mouse lines, the first genetic models of this disease. They established two things that changed the field. The hypoplasia is underpinned by intrinsic cardiomyocyte proliferation and differentiation defects rather than being purely haemodynamic, and the disease is genetically heterogeneous and multigenic rather than attributable to one locus. Similar but milder defects in the right ventricle in these models are the animal counterpart of the late systemic right ventricular failure seen in patients.
Organism
house mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in house mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Publication
PMID:29569026
Pathograph links
Impaired cardiomyocyte proliferation and differentiation The models demonstrate cell-autonomous proliferation and differentiation defects underlying the hypoplasia.
Genetic lesion affecting cardiac growth or valvulogenesis Eight independent lines establish the multigenic architecture the trigger node describes.
Show evidence (2 references)
PMID:29569026 SUPPORT Model Organism
"Analysis of 8 independent HLHS mouse lines showed HLHS is genetically heterogeneous and multigenic in etiology."
Establishes the multigenic architecture from independently derived lines rather than from a single mutant.
PMID:29569026 SUPPORT Model Organism
"The findings of similar defects of lesser severity in the right ventricle suggest this could contribute to the heart failure risks in surgically palliated HLHS patients."
Provides the model-organism counterpart of the recessive-variant finding in patients, that the right ventricle is not a normal chamber pressed into abnormal service but is itself affected.
{ }

Source YAML

click to show 
name: Hypoplastic Left Heart Syndrome
creation_date: "2026-08-10T03:40:00Z"
category: Congenital
disease_term:
  preferred_term: hypoplastic left heart syndrome
  term:
    id: MONDO:0004933
    label: hypoplastic left heart syndrome
description: >
  Underdevelopment of the entire left side of the heart, from the mitral valve through the left
  ventricle and aortic valve to the ascending aorta and arch, such that the left heart cannot
  support the systemic circulation. Two features make it unusual among congenital heart defects.
  The first is that its cause is genuinely unsettled, and the argument is not about which gene
  but about which kind of thing starts the disease. One account says an intrinsic myocardial or
  valvar defect comes first and the small chamber follows from it. The other says an obstruction
  reduces flow through the left heart in mid-gestation and the chamber fails to grow because it
  is not being used. Both have direct experimental support, and the most informative recent work
  does not choose between them so much as nest one inside the other. The second is that the
  treatment does not repair anything. Staged palliation rearranges the circulation so that the
  right ventricle pumps to the body and venous blood reaches the lungs without a pump at all.
  Every late problem these patients face, and there are many, belongs to the physiology of that
  reconstruction rather than to the original malformation. Fewer than a third are alive without
  a transplant at thirty-five years, and that figure has stopped improving.
parents:
- congenital heart malformation
- univentricular heart

classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
    notes: >-
      A structural congenital cardiovascular malformation. The neurodevelopmental and hepatic
      sequelae of the palliated circulation fall outside this chapter but are consequences of the
      cardiac lesion and its treatment rather than independent disease.

has_subtypes:
- name: Aortic atresia
  display_name: Hypoplastic left heart syndrome with aortic atresia
  description: >
    The severe end of the spectrum, in which the aortic valve is imperforate. It matters
    mechanistically rather than only descriptively, because with no antegrade flow the ascending
    aorta becomes a retrograde-perfused conduit whose only function is to supply the coronary
    arteries. Coronary perfusion is then ductal-dependent, which is why ductal closure in this
    subtype threatens the myocardium and not only the systemic circulation.
- name: Aortic stenosis with mitral stenosis
  display_name: Hypoplastic left heart syndrome with patent but stenotic valves
  description: >
    Some antegrade flow persists through hypoplastic but perforate valves. This is the subtype in
    which the disease can be watched developing before birth, and the subtype in which fetal
    intervention has been attempted, because there is a lumen to open.
- name: Evolving HLHS from critical aortic stenosis
  display_name: Evolving hypoplastic left heart syndrome
  description: >
    A mid-gestation fetus with critical aortic stenosis and a left ventricle that is still of
    adequate size, which progresses to established hypoplasia by term if the obstruction is not
    relieved. It is curated as a subtype because it is the only setting in which the natural
    history of the disease is observable prospectively, and because it is the group in which the
    flow theory makes a testable prediction.

inheritance:
- name: Complex non-Mendelian inheritance
  description: >
    The dominant pattern. Family clustering establishes that this disease and related left-sided
    malformations are heritable, and genomic regions influencing that inheritance have been
    identified, yet single causal variants have not been found in most patients. The conclusion
    drawn in the field is not that the genetics are unknown but that the inheritance model is
    wrong, that expecting one disease-causing variant is the error. That is why this entry curates
    the genetic contribution as a distributed input to a convergent phenotype rather than as a
    causal gene, and why simple recurrence-risk counselling is not available.
  inheritance_term:
    preferred_term: Non-Mendelian inheritance
    term:
      id: HP:0001426
      label: Non-Mendelian inheritance
  evidence:
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, using simple Mendelian inheritance models, identification of single genetic variants that \"cause\" HLHS has remained elusive, and in most cases, the genetic cause remains unknown. These results suggest that HLHS inheritance is complex rather than simple."
    explanation: >-
      States the conclusion this inheritance record encodes, that the inheritance is complex
      rather than that the genetics are merely undiscovered.
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Second, studies of family clustering of HLHS and related cardiovascular malformations have determined HLHS is heritable. Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
    explanation: >-
      Establishes heritability and mapped contributing regions, which is what makes the absence of
      single causal variants informative rather than simply a gap in ascertainment.

- name: Autosomal recessive, sarcomeric
  description: >
    A minority mechanism rather than the disease's general mode, applying to the compound
    heterozygous MYH6 route curated in the genetic section. It is recorded because it carries a
    counselling consequence the complex pattern does not, namely a defined sibling recurrence
    risk, and because the unaffected heterozygous parents and siblings in those families are what
    establish the mode.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parents and siblings who were heterozygous carriers had normal echocardiograms."
    explanation: >-
      Unaffected carriers in the same families are the observation that establishes recessive
      rather than dominant transmission for this route. Graded PARTIAL because two families
      cannot establish how large a share of the disease this mode accounts for.

mechanistic_hypotheses:
- hypothesis_group_id: flow_theory
  hypothesis_label: Flow theory, no flow no grow
  status: CANONICAL
  description: >-
    An initiating obstruction at the mitral or aortic valve reduces flow through the left heart
    in mid-gestation, and the chamber, valves, and ascending aorta fail to grow because
    shear-dependent growth signalling is lost. On this account the hypoplasia is secondary and
    the primary lesion is mechanical. It is the model that predicts serial fetal echocardiography
    showing progression from isolated critical aortic stenosis to established hypoplasia, and it
    is the model that motivates fetal aortic valvuloplasty.
  evidence:
  - reference: PMID:42200818
    reference_title: "Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The flow theory is strongly supported by animal models and in utero interventions that demonstrate the impact of altered hemodynamics on cardiac morphogenesis."
    explanation: >-
      States both the support for the model and its two sources, animal work and the human
      intervention. Evidence source is OTHER because this is a review evaluating competing models
      rather than a primary study.
  - reference: PMID:42200818
    reference_title: "Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation."
    supports: REFUTE
    evidence_source: OTHER
    snippet: "However, the flow theory fails to identify initial causes of disturbed flow or related histological features of HLHS like endocardial fibroelastosis."
    explanation: >-
      The same review's statement of what the model cannot account for, curated alongside the
      support so the hypothesis is recorded with its limits rather than as settled. It is a
      REFUTE of the model's sufficiency, not of its contribution.

- hypothesis_group_id: intrinsic_myocardial_defect
  hypothesis_label: Intrinsic myocardial and cell-autonomous defect
  status: ALTERNATIVE
  description: >-
    A primary defect of cardiomyocyte proliferation, differentiation, or sarcomeric function
    limits growth of the left heart directly, with the flow deficit a consequence rather than a
    cause. The strongest form of this argument is not that flow is irrelevant but that the flow
    deficit is itself downstream of a myocardial defect, which is what a myocardium-restricted
    genetic rescue of the structural phenotype demonstrates.
  evidence:
  - reference: PMID:29569026
    reference_title: "The Genetic Landscape of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Current paradigm suggests HLHS is largely of hemodynamic origin, but recent findings from analysis of the first mouse model of HLHS showed intrinsic cardiomyocyte proliferation and differentiation defects underlying the left ventricular (LV) hypoplasia."
    explanation: >-
      States the challenge to the haemodynamic paradigm and its source in the first genetic mouse
      model of the disease.
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This work supports an emerging paradigm for HLHS pathogenesis that centers on myocardial intrinsic defects."
    explanation: >-
      A second, independent model system reaching the same conclusion, which is what raises this
      from a single-model result to a competing account.

- hypothesis_group_id: myocardial_defect_upstream_of_flow
  hypothesis_label: Myocardial defect upstream of the flow deficit
  status: EMERGING
  description: >-
    A reconciliation rather than a third competitor. On this account an intrinsic myocardial
    defect impairs pump function, the impaired pump produces the flow deficit, and the flow
    deficit produces the structural hypoplasia, so both earlier models describe true steps in one
    sequence. The evidence is a genetic rescue with anatomical specificity. Restoring the gene
    only in myocardium rescues the ventricular, valve, and aortic phenotypes together, which is
    what one expects if all three are downstream of pump function and not if they are independent
    lesions. This is recorded as EMERGING because it rests on one model organism.
  evidence:
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In contrast to current models, we demonstrate that these structural deficits arise secondary to impaired pump function as these phenotypes are rescued when Rbfox is specifically expressed in the myocardium."
    explanation: >-
      The tissue-restricted rescue is what makes this more than a correlation. It places the
      myocardial defect upstream of the structural deficits while leaving the flow-dependence of
      those deficits intact.
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we report that zebrafish lacking two orthologs of the RNA binding protein RBFOX2, a gene linked to HLHS in humans, display cardiovascular defects overlapping those in HLHS patients including ventricular, valve, and aortic deficiencies."
    explanation: >-
      Establishes what the model reproduces. Graded PARTIAL because a zebrafish, which has a
      two-chambered heart and no left ventricle in the mammalian sense, can model the mechanism
      without modelling the anatomy.
  notes: >
    Recorded as a distinct hypothesis rather than folded into either parent because it makes a
    different prediction from both. The flow theory predicts that relieving obstruction should
    rescue growth regardless of myocardial genotype, and the intrinsic-defect model predicts that
    relieving obstruction should not help. This one predicts that relief should help partially and
    variably, depending on how much of the pump deficit is mechanical, which is closer to what
    fetal aortic valvuloplasty actually achieves.

pathophysiology:
- name: Genetic lesion affecting cardiac growth or valvulogenesis
  biological_scale: MOLECULAR
  description: >
    Variants in cardiac transcription factors, signalling genes, sarcomeric genes, and chromatin
    regulators contribute to the disease, but not in the way a Mendelian disorder does. Eight
    independent mouse lines produce the phenotype, the human genetic architecture combines de
    novo single-gene and copy-number lesions with lower-penetrance and common variation, and no
    single gene accounts for more than a small fraction of cases. That architecture is itself a
    mechanistic claim, because it says the phenotype is a convergence point reachable by many
    routes rather than the readout of one pathway.
  biological_processes:
  - preferred_term: cardiac ventricle development
    term:
      id: GO:0003231
      label: cardiac ventricle development
    modifier: DECREASED
  - preferred_term: heart valve development
    term:
      id: GO:0003170
      label: heart valve development
    modifier: DECREASED
  evidence:
  - reference: PMID:36286267
    reference_title: "Considering the Genetic Architecture of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "De novo single-gene and copy number variant (CNV) disorders make an important contribution, but there is emerging evidence for causal contributions from lower penetrance and common variation."
    explanation: >-
      States the mixed architecture, which is the basis for modelling the genetic contribution as
      a distributed input to a convergent phenotype rather than as a causal gene.
  - reference: PMID:29569026
    reference_title: "The Genetic Landscape of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Analysis of 8 independent HLHS mouse lines showed HLHS is genetically heterogeneous and multigenic in etiology."
    explanation: >-
      Supports genetic heterogeneity from the model-organism side, independently of the human
      sequencing data.
  downstream:
  - target: Impaired cardiomyocyte proliferation and differentiation
    causal_link_type: DIRECT
    hypothesis_groups:
    - intrinsic_myocardial_defect
    - myocardial_defect_upstream_of_flow
    description: >
      On the intrinsic-defect account the genetic lesion acts first on the myocyte, limiting
      growth of the chamber directly.
  - target: Obstruction to left heart inflow or outflow
    causal_link_type: DIRECT
    hypothesis_groups:
    - flow_theory
    description: >
      On the flow account the genetic lesion acts on valvulogenesis, and the mechanical
      consequence rather than the myocyte defect is what limits growth.

- name: Impaired cardiomyocyte proliferation and differentiation
  biological_scale: CELLULAR
  description: >
    Cardiomyocytes in the developing left ventricle proliferate less and differentiate abnormally,
    with disorganised sarcomeric architecture and altered mitochondrial maturation. This is what
    the first genetic mouse model of the disease showed, and it is the node that distinguishes an
    intrinsically small ventricle from a ventricle that is small because it is unused.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  evidence:
  - reference: PMID:29569026
    reference_title: "The Genetic Landscape of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Current paradigm suggests HLHS is largely of hemodynamic origin, but recent findings from analysis of the first mouse model of HLHS showed intrinsic cardiomyocyte proliferation and differentiation defects underlying the left ventricular (LV) hypoplasia."
    explanation: >-
      Directly supports impaired proliferation and differentiation as the cellular lesion beneath
      the hypoplasia in a genetic model.
  downstream:
  - target: Reduced flow through the left heart
    causal_link_type: DIRECT
    hypothesis_groups:
    - myocardial_defect_upstream_of_flow
    description: >
      A myocardium that cannot pump adequately generates less flow, which is the reconciliation
      the tissue-restricted rescue experiment supports.
  - target: Progressive hypoplasia of left heart structures
    causal_link_type: DIRECT
    hypothesis_groups:
    - intrinsic_myocardial_defect
    description: >
      On the strict intrinsic-defect account the small chamber follows from the cell-autonomous
      growth defect without requiring a flow intermediate.

- name: Obstruction to left heart inflow or outflow
  biological_scale: TISSUE
  description: >
    Stenosis or atresia of the mitral or aortic valve. In the evolving form this is present in
    mid-gestation while the left ventricle is still of adequate size, so the obstruction can be
    observed before the hypoplasia it is proposed to cause.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  - preferred_term: mitral valve
    term:
      id: UBERON:0002135
      label: mitral valve
  downstream:
  - target: Reduced flow through the left heart
    causal_link_type: DIRECT
    hypothesis_groups:
    - flow_theory
    description: >
      A stenotic or atretic valve mechanically limits the volume traversing the left heart.

- name: Reduced flow through the left heart
  biological_scale: ORGANISM
  description: >
    Whatever puts it there, reduced flow across the mitral valve and out through the aortic valve
    is the shared middle of the disease. The claim attached to it is that flow is not merely a
    consequence of chamber size but an input to chamber growth, so that a left heart carrying
    less volume grows less. That claim is testable in humans, and it has been tested.
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  downstream:
  - target: Progressive hypoplasia of left heart structures
    causal_link_type: DIRECT
    hypothesis_groups:
    - flow_theory
    - myocardial_defect_upstream_of_flow
    description: >
      Loss of the flow-dependent growth stimulus arrests growth of the chamber, its valves, and
      the ascending aorta together.
  - target: Endocardial fibroelastosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Abnormal endocardial shear is associated with a fibroelastic lining of the ventricular
      cavity, though the flow account does not by itself explain this lesion.

- name: Endocardial fibroelastosis
  biological_scale: TISSUE
  description: >
    A layer of fibroelastic tissue lining the hypoplastic ventricular cavity, further reducing
    compliance and inflow. It is curated as its own node because it is the specific finding the
    flow theory is criticised for failing to explain, so collapsing it into the hypoplasia node
    would hide the weakness in the model.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  evidence:
  - reference: PMID:42200818
    reference_title: "Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "However, the flow theory fails to identify initial causes of disturbed flow or related histological features of HLHS like endocardial fibroelastosis."
    explanation: >-
      Identifies endocardial fibroelastosis as a histological feature the dominant model does not
      account for, which is why this entry gives it a node rather than treating it as detail.
      Evidence source is OTHER because this is a review.
  notes: >
    No biological_processes annotation is attached, and the reason is evidential rather than
    terminological. An earlier draft bound this node to GO:0001837 epithelial to mesenchymal
    transition, which is the wrong process. The literature describes endothelial-to-mesenchymal
    transition, a distinct event in which endocardial endothelium rather than epithelium acquires
    a mesenchymal phenotype. An apt term for that process does exist. GO:0140074 cardiac
    endothelial to mesenchymal transition carries EndMT and EndoMT as exact synonyms, and its
    definition reaches beyond endocardial cushion and valve formation to the generation of
    cardiac fibroblasts and smooth muscle cells, which is the population a fibroelastic lesion
    would draw on. It is deliberately not used here. The evidence cited on this node establishes
    only that the lesion exists and is unexplained by the flow model, and does not establish that
    any cell-state transition occurs, so binding GO:0140074 would attach a mechanism claim this
    entry cannot support. A future curator who arrives with evidence for the transition itself
    should use that term. The cell types are retained because the cellular participants are not
    in doubt.
  downstream:
  - target: Progressive hypoplasia of left heart structures
    causal_link_type: DIRECT
    description: >
      A non-compliant cavity lining further restricts filling and therefore further restricts the
      volume available to drive growth.

- name: Progressive hypoplasia of left heart structures
  biological_scale: TISSUE
  description: >
    By term the mitral valve, left ventricle, aortic valve, and ascending aorta and arch are all
    markedly undersized or atretic. The word progressive is doing real work here. This is not a
    malformation fixed at the moment of organogenesis but one that develops across gestation,
    which is precisely why a mid-gestation intervention is conceivable at all.
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  - preferred_term: ascending aorta
    term:
      id: UBERON:0001496
      label: ascending aorta
  - preferred_term: arch of aorta
    term:
      id: UBERON:0001508
      label: arch of aorta
  downstream:
  - target: Ductus-dependent systemic and coronary perfusion
    causal_link_type: DIRECT
    description: >
      A left heart that cannot eject to the body leaves the systemic circulation dependent on
      right-to-left flow through the arterial duct.
  - target: Restrictive or intact atrial septum
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Because a hypoplastic or atretic mitral valve gives the left atrium no forward outlet, the
      adequacy of the interatrial communication becomes the sole determinant of whether pulmonary
      venous return can escape.

- name: Restrictive or intact atrial septum
  biological_scale: ORGANISM
  description: >
    The left atrium in this disease receives the entire pulmonary venous return and has no
    outlet through a hypoplastic or atretic mitral valve, so that blood can only leave across the
    atrial septum. When the interatrial communication is small or absent the pulmonary veins
    are obstructed in utero, and the consequence is not merely haemodynamic. Sustained pulmonary
    venous hypertension remodels the lung itself, producing pulmonary lymphangiectasia, so the
    child is born with lung disease as well as heart disease. This is why an intact septum
    converts an operable malformation into an emergency at the moment of delivery, and why it is
    the single prenatal finding that most changes prognosis.
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:41185129
    reference_title: "Fetal Diagnosis of Hypoplastic Left Heart Syndrome With Restrictive Atrial Septum-Atrial Septal Morphology, Associated Lung Disease and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fetuses with hypoplastic left heart syndrome (HLHS) and restrictive/intact atrial septum (RAS) have high mortality, partly due to pulmonary lymphangiectasia (PL)."
    explanation: >-
      States both the prognostic weight of the finding and the mechanism by which it kills, which
      is lung remodelling rather than the cardiac lesion alone.
  - reference: PMID:41185129
    reference_title: "Fetal Diagnosis of Hypoplastic Left Heart Syndrome With Restrictive Atrial Septum-Atrial Septal Morphology, Associated Lung Disease and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most had a hypoplastic left atrium (LA, 80%). Four atrial septal morphology patterns were identified. PL was present among all patterns and associated with lower VTI ratio (p = 0.046)."
    explanation: >-
      Links the degree of obstruction, measured as the pulmonary venous flow ratio, to the lung
      lesion, which is what makes this a graded mechanism rather than a binary anatomical finding.
  downstream:
  - target: Circulatory collapse on ductal closure
    causal_link_type: DIRECT
    description: >
      An obstructed interatrial communication compounds the postnatal emergency, since pulmonary
      venous return cannot reach the systemic circulation even while the duct remains open.

- name: Ductus-dependent systemic and coronary perfusion
  biological_scale: ORGANISM
  description: >
    After birth the entire systemic output crosses the arterial duct from the pulmonary artery,
    and the right ventricle supplies both circulations in parallel. In aortic atresia the
    ascending aorta carries only retrograde flow to the coronary arteries, so the coronary supply
    is ductal-dependent too. Systemic and pulmonary flow now compete for the same output, which
    is why a fall in pulmonary vascular resistance after birth paradoxically worsens systemic
    perfusion by stealing flow into the lungs.
  locations:
  - preferred_term: ascending aorta
    term:
      id: UBERON:0001496
      label: ascending aorta
  downstream:
  - target: Circulatory collapse on ductal closure
    causal_link_type: DIRECT
    description: >
      Closure of the duct removes the only route by which blood reaches the body and, in aortic
      atresia, the heart itself.

- name: Circulatory collapse on ductal closure
  biological_scale: ORGANISM
  description: >
    The duct closes over the first days of life and systemic perfusion fails, producing shock,
    acidosis, and death. This is the reason the disease is uniformly fatal untreated and the
    reason prostaglandin infusion is the first intervention, since keeping the duct open buys the
    time in which everything else becomes possible.
  downstream:
  - target: Systemic right ventricle after staged palliation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >
      Surgical palliation prevents the collapse and substitutes a reconstructed circulation, which
      is the state the patient then lives in.

- name: Systemic right ventricle after staged palliation
  biological_scale: ORGANISM
  description: >
    The reconstruction leaves the right ventricle pumping to the body and, after the final stage,
    venous blood flowing to the lungs without a ventricle behind it. This is not a repair and the
    entry curates it as a disease state rather than as an outcome. The right ventricle is not
    built for systemic afterload and eventually fails in a substantial proportion. There is also
    evidence that this failure is not purely mechanical wear, since recessive sarcomeric variants
    found in patients who developed late right ventricular dysfunction suggest the same molecular
    defect that arrested the left ventricle can express itself later as a myopathy of the right.
    Patients with this disease do worse after the same operation than patients with other
    single-ventricle anatomies, which is consistent with something intrinsic to the myocardium
    rather than to the plumbing.
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart right ventricle
    term:
      id: UBERON:0002080
      label: heart right ventricle
  evidence:
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings implicate a shared molecular basis for the developmental arrest and latent myopathy of left and right ventricles, respectively."
    explanation: >-
      The specific claim this node makes, that late right ventricular failure may be a delayed
      expression of the same molecular lesion rather than only the cost of systemic afterload.
  - reference: PMID:39604028
    reference_title: "Cardiovascular Outcomes Associated With Hypoplastic Left Heart Syndrome Versus Other Types of Single Right Ventricle: A Multicenter Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In multivariable analyses, HLHS was associated with a significantly higher risk of the composite outcome"
    explanation: >-
      Compares this disease against other anatomies palliated the same way and with the same
      systemic right ventricle, so the excess risk is attributable to something in the disease
      rather than to the operation. This is the epidemiological counterpart of the genetic
      argument above.

phenotypes:
- category: Cardiovascular
  name: Hypoplastic left ventricle
  description: >
    A left ventricle too small to support the systemic circulation, the defining structural
    lesion.
  phenotype_term:
    preferred_term: Hypoplastic left ventricle
    term:
      id: HP:0004383
      label: Hypoplastic left ventricle
    clinical_course: PROGRESSIVE

- category: Cardiovascular
  name: Aortic valve atresia
  description: >
    Imperforate aortic valve, present in the most severe subtype and the reason the ascending
    aorta becomes a retrograde coronary conduit.
  phenotype_term:
    preferred_term: Aortic valve atresia
    term:
      id: HP:0010883
      label: Aortic valve atresia

- category: Cardiovascular
  name: Mitral atresia
  description: >
    Imperforate mitral valve, eliminating inflow to the left ventricle and commonly co-occurring
    with aortic atresia.
  phenotype_term:
    preferred_term: Mitral atresia
    term:
      id: HP:0011560
      label: Mitral atresia

- category: Cardiovascular
  name: Patent ductus arteriosus
  description: >
    Persistence of the arterial duct, which in this disease is not a defect but the only route by
    which blood reaches the body. Its patency is maintained pharmacologically until surgery,
    inverting the usual clinical significance of the finding.
  phenotype_term:
    preferred_term: Patent ductus arteriosus
    term:
      id: HP:0001643
      label: Patent ductus arteriosus

- category: Cardiovascular
  name: Endocardial fibroelastosis
  description: >
    Fibroelastic thickening of the ventricular endocardium, reducing compliance. It is the
    histological finding that the dominant flow-based model of the disease does not account for.
  phenotype_term:
    preferred_term: Endocardial fibroelastosis
    term:
      id: HP:0001706
      label: Endocardial fibroelastosis

- category: Sign
  name: Cyanosis
  description: >
    Blue discoloration from the obligate mixing of systemic and pulmonary venous return in a
    single functional ventricle. Unlike in tetralogy of Fallot the mixing is anatomically
    unavoidable rather than dependent on shunt direction.
  phenotype_term:
    preferred_term: Cyanosis
    term:
      id: HP:0000961
      label: Cyanosis

- category: Sign
  name: Cardiogenic shock on ductal closure
  description: >
    Circulatory collapse over the first days of life as the duct closes, with acidosis and
    end-organ hypoperfusion. It is the presentation in any infant not diagnosed before birth or
    on newborn pulse oximetry screening.
  phenotype_term:
    preferred_term: Cardiogenic shock
    term:
      id: HP:0030149
      label: Cardiogenic shock
    temporality: ACUTE
    severity: SEVERE

- category: Cardiovascular
  name: Coarctation of the aorta
  description: >
    Narrowing of the aorta at the ductal insertion, frequently co-occurring and relevant because
    it further compromises the retrograde systemic supply on which the patient depends.
  phenotype_term:
    preferred_term: Coarctation of aorta
    term:
      id: HP:0001680
      label: Coarctation of aorta

- category: Cardiovascular
  name: Right ventricular failure after palliation
  description: >
    Late failure of the systemic right ventricle, the dominant cause of death or transplantation
    in survivors. It is a phenotype of the reconstructed circulation rather than of the
    malformation, and there is evidence that it may also be a delayed expression of the same
    myocardial defect.
  phenotype_term:
    preferred_term: Right ventricular failure
    term:
      id: HP:0001708
      label: Right ventricular failure
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Evaluation of cardiac structure and function by echocardiography in patients with hypoplastic left heart and their first-degree relatives identified 5 individuals with right ventricular ejection fraction ≤40% after Fontan operation."
    explanation: >-
      Documents the phenotype in a Fontan-palliated cohort with an explicit functional threshold.

genetic:
- name: MYH6
  gene_term:
    preferred_term: MYH6
    term:
      id: hgnc:7576
      label: MYH6
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    Encodes alpha-myosin heavy chain. It is the gene with the strongest statistical support in
    this disease, enriched by rare-variant burden testing against controls, and the one with the
    most interesting clinical implication, since compound heterozygous recessive variants were
    found in patients who later developed systemic right ventricular dysfunction. That connects
    the developmental lesion to the late complication through one molecule.
  evidence:
  - reference: PMID:33325730
    reference_title: "Genetic Association Between Hypoplastic Left Heart Syndrome and Cardiomyopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "rare variant burden testing of 56 genes revealed enrichment in MYH6 (P=0.000068)"
    explanation: >-
      Provides the case-control burden evidence, which is stronger than the family-based findings
      alone.
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Secondary family-based filtering for de novo and recessive variants revealed rare inherited missense mutations on both paternal and maternal alleles of MYH6, encoding myosin heavy chain 6, in 2 patients who developed right ventricular dysfunction 3 to 11 years postoperatively."
    explanation: >-
      Establishes the recessive mode and its association with the late right ventricular
      phenotype, which is the specific claim the systemic right ventricle node depends on.
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parents and siblings who were heterozygous carriers had normal echocardiograms."
    explanation: >-
      Supports recessive inheritance for this mechanism by showing carriers are unaffected.
      Graded PARTIAL because the number of families is very small.

- name: NOTCH1
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    A receptor central to valvulogenesis, endocardial cushion formation, and ventricular
    trabeculation, and one of the recurrently implicated genes in left-sided obstructive lesions
    generally. No frequency or effect size is asserted, since this entry cites no
    cohort-frequency evidence for it. The evidence attached is about the class of finding rather
    than this locus specifically, which is the honest position for a gene identified through
    mapped genomic regions rather than through a replicated association.
  evidence:
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
    explanation: >-
      Supports the existence of mapped genomic contributions, which is the category this gene
      belongs to. Graded PARTIAL because it does not name this locus and therefore cannot
      establish its individual contribution.

- name: NKX2-5
  gene_term:
    preferred_term: NKX2-5
    term:
      id: hgnc:2488
      label: NKX2-5
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    A cardiac transcription factor with an OMIM-designated hypoplastic left heart syndrome
    subtype. As with NOTCH1, no frequency or effect size is asserted here.
  evidence:
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Third, genomic regions that encode genes influencing the inheritance of HLHS have been identified."
    explanation: >-
      As for NOTCH1, this supports the category rather than the locus. Graded PARTIAL for the
      same reason, and the two genes are curated at the same evidential strength deliberately,
      since neither has cohort-frequency evidence cited here.

- name: Cytogenetic abnormality
  gene_term:
    preferred_term: chromosomal abnormality associated with hypoplastic left heart syndrome
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    A minority of cases occur in the context of a chromosomal abnormality, Turner syndrome being
    the recurrently cited example. This is curated as a named genetic contribution without a gene
    binding, because the lesion is a chromosome rather than a locus and no single gene is being
    asserted. Its evidential role in this entry is specific. Cytogenetic association is one of
    the three independent lines of argument that the disease has genetic origins, alongside
    family clustering and mapped genomic regions, and it is the line that is hardest to explain
    on a purely haemodynamic account. No frequency is asserted, since this entry cites no source
    quantifying the syndromic share.
  evidence:
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "First, some HLHS cases have been associated with cytogenetic abnormalities (e.g., Turner syndrome)."
    explanation: >-
      Establishes the cytogenetic association and names the recurrent example, which is the whole
      of the claim this record makes.

- name: RBFOX2
  gene_term:
    preferred_term: RBFOX2
    term:
      id: hgnc:9906
      label: RBFOX2
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  notes: >
    An RNA-binding splicing regulator linked to this disease in humans and the gene whose
    zebrafish orthologue loss produced the tissue-restricted rescue experiment that underlies the
    reconciling hypothesis in this entry. Its interest here is mechanistic rather than
    epidemiological.
  evidence:
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Injection of human RBFOX2 mRNA restores cardiovascular development in rbfox mutant zebrafish, while HLHS-linked RBFOX2 variants fail to rescue."
    explanation: >-
      Functional evidence that the human variants are loss of function, since wild-type human
      messenger RNA rescues and the patient variants do not. Graded PARTIAL because the assay is
      cross-species complementation rather than a human genetic association.

treatments:
- name: Prostaglandin E1 infusion
  description: >
    Maintains ductal patency from birth until surgery. It does nothing to the malformation and
    is not a treatment of the disease in any mechanistic sense, but without it the patient dies
    of the next node in the chain within days.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prostaglandin E1
      term:
        id: CHEBI:15544
        label: prostaglandin E1
  target_mechanisms:
  - target: Circulatory collapse on ductal closure
    treatment_effect: INHIBITS
    description: >
      Preventing ductal closure preserves the only route by which blood reaches the systemic and,
      in aortic atresia, the coronary circulation.
  evidence:
  - reference: PMID:40390868
    reference_title: "Caffeine Treatment for Prostaglandin E1-Induced Apnea Prevention in Congenital Heart Disease Neonates: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prostaglandin E1 (PGE1) is used to maintain the ductus arteriosus open in neonates with ductal-dependent heart lesions but is associated with apnea."
    explanation: >-
      States both the indication this treatment is curated for and its principal toxicity in the
      same sentence. Apnoea matters practically, since it is the reason these neonates are often
      intubated for transport rather than for their cardiac lesion.

- name: Balloon atrial septostomy
  description: >
    Catheter enlargement of the interatrial communication, performed urgently after birth when
    the septum is restrictive or intact, and increasingly attempted before birth. It is the
    direct counterpart of the restrictive-septum emergency, and the fetal version is the second
    intervention in this disease that acts on mechanism rather than consequence. Fetal atrial
    septal intervention improves the measured degree of pulmonary venous obstruction, and in some
    fetuses the associated lung lesion improves too. Whether that translates into survival is not
    established, since mortality in the reported series did not differ by whether intervention was
    performed.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Restrictive or intact atrial septum
    treatment_effect: INHIBITS
    description: >
      Enlarging the interatrial communication relieves the obstruction to pulmonary venous
      egress, which is the lesion driving the lung disease.
  evidence:
  - reference: PMID:41185129
    reference_title: "Fetal Diagnosis of Hypoplastic Left Heart Syndrome With Restrictive Atrial Septum-Atrial Septal Morphology, Associated Lung Disease and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean VTI ratio improved in fetuses who underwent atrial septal intervention (n = 12), compared to those without (p = 0.001)."
    explanation: >-
      Establishes that the intervention relieves the physiological obstruction it targets, which
      is the mechanistic claim rather than the outcome claim.
  - reference: PMID:41185129
    reference_title: "Fetal Diagnosis of Hypoplastic Left Heart Syndrome With Restrictive Atrial Septum-Atrial Septal Morphology, Associated Lung Disease and Outcomes."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seventeen neonates were live-born with intention-to-treat; 6-months mortality was 38% with no difference by morphology pattern, PL, or fetal intervention."
    explanation: >-
      Bounds the claim deliberately. The physiological target improves while mortality does not
      differ, so this entry curates the intervention as mechanism-directed without asserting
      survival benefit. Graded INDIRECT for that reason.

- name: Staged single-ventricle palliation
  description: >
    Three operations converting a parallel, ductal-dependent circulation into a series
    circulation with the right ventricle as the systemic pump and passive venous return to the
    lungs. It is the reason the disease is survivable and it is also the origin of the disease
    these patients live with afterwards. In the largest long-term cohort fewer than a third were
    alive without transplantation at thirty-five years, and survival has not improved in recent
    eras, which is a statement about the limits of the approach rather than about surgical
    technique.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Ductus-dependent systemic and coronary perfusion
    treatment_effect: INHIBITS
    description: >
      Reconstruction gives the right ventricle a permanent unobstructed path to the aorta,
      removing the dependence on the duct.
  evidence:
  - reference: PMID:40533128
    reference_title: "Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Transplant-free survival was 31.0% at 35 years. Transplant-free survival improved over time but is not different across recent eras."
    explanation: >-
      Quantifies both the survival achieved and the plateau. Graded PARTIAL because it supports
      the operation as life-prolonging while simultaneously bounding what it achieves, which is
      the balanced claim this entry makes.

- name: Fetal aortic valvuloplasty
  description: >
    Catheter dilation of a stenotic aortic valve in mid-gestation, attempted in fetuses with
    critical aortic stenosis whose left ventricle has not yet become hypoplastic. It is the only
    treatment in this disease that acts on mechanism rather than on consequence, and it is
    simultaneously the strongest human test of the flow theory, since it predicts that relieving
    obstruction should permit left heart growth. It partly does. Just over forty percent of
    live-born fetuses in the largest series achieved a biventricular circulation, and their
    left-sided structures were significantly larger at birth. Most still required postnatal
    intervention, so the result supports flow-dependent growth without supporting a cure.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Obstruction to left heart inflow or outflow
    treatment_effect: INHIBITS
    description: >
      Dilating the stenotic valve restores antegrade flow through the left heart during the
      gestational window in which the chamber is still growing.
  evidence:
  - reference: PMID:25052401
    reference_title: "Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eighty-eight fetuses were live-born, and 38 had a BV circulation (31 from birth, 7 converted after initial univentricular palliation)."
    explanation: >-
      Quantifies how often the intervention achieved a two-ventricle circulation, which is the
      outcome the flow theory predicts should be attainable.
  - reference: PMID:25052401
    reference_title: "Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Left-sided structures, namely aortic and mitral valve sizes and left ventricular volume, were significantly larger in the BV group at the time of birth (P<0.01)."
    explanation: >-
      This is the mechanistic result rather than the clinical one. Structures downstream of the
      relieved obstruction were larger, which is the growth response the flow theory posits.
  - reference: PMID:25052401
    reference_title: "Fetal aortic valvuloplasty for evolving hypoplastic left heart syndrome: postnatal outcomes of the first 100 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All but 1 of the BV patients required postnatal intervention; 42% underwent aortic or mitral valve replacement."
    explanation: >-
      Bounds the claim. A biventricular circulation is not a normal heart, and curating this
      alongside the successes keeps the entry from overstating what relieving the obstruction
      achieves. Graded PARTIAL for that reason.

- name: Cardiac transplantation
  description: >
    Replacement of the heart, used when the systemic right ventricle fails or when palliation is
    not feasible. It is the only treatment that removes the underlying myocardium, which matters
    if the late failure is partly a myopathy rather than only afterload mismatch, and it is
    limited by donor availability in the relevant age group.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Organ Transplantation
    term:
      id: NCIT:C15289
      label: Organ Transplantation
  target_mechanisms:
  - target: Systemic right ventricle after staged palliation
    treatment_effect: INHIBITS
    description: >
      Transplantation replaces the failing systemic ventricle and, with it, any intrinsic
      myocardial defect it carried.

experimental_models:
- name: Rbfox-deficient zebrafish
  description: >
    Zebrafish lacking both orthologues of RBFOX2, which develop ventricular, valve, and aortic
    deficiencies overlapping the human phenotype. Its importance is not that it phenocopies the
    disease but that it can be dissected. Restoring the gene only in myocardium rescues the
    structural phenotypes, which places the myocardial defect upstream of the flow deficit and
    upstream of the structural lesions, and human wild-type messenger RNA rescues while
    patient-derived variants do not, which establishes those variants as loss of function. Its
    limitation is anatomical, since the zebrafish heart has one ventricle and no left heart in the
    mammalian sense, so the model can support the mechanism without supporting the anatomy.
  experimental_model_type: OTHER
  organism:
    preferred_term: zebrafish
    term:
      id: NCBITaxon:7955
      label: Danio rerio
  modeled_mechanisms:
  - target: Impaired cardiomyocyte proliferation and differentiation
    description: >
      The model localises the primary defect to the myocardium by tissue-restricted rescue.
  - target: Reduced flow through the left heart
    description: >
      It places the flow deficit downstream of impaired pump function rather than upstream of the
      myocardial phenotype.
  publication: PMID:36198703
  evidence:
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In contrast to current models, we demonstrate that these structural deficits arise secondary to impaired pump function as these phenotypes are rescued when Rbfox is specifically expressed in the myocardium."
    explanation: >-
      The tissue-restricted rescue, which is the experiment that makes this model informative
      about causal order rather than only about phenotype.
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Mechanistically, we find diminished expression and alternative splicing of sarcomere and mitochondrial components that compromise sarcomere assembly and mitochondrial respiration, respectively."
    explanation: >-
      Identifies the molecular consequence, which connects a splicing regulator to the contractile
      and energetic machinery a pump depends on.

- name: Genetic mouse models of hypoplastic left heart
  description: >
    A panel of independently derived mouse lines, the first genetic models of this disease. They
    established two things that changed the field. The hypoplasia is underpinned by intrinsic
    cardiomyocyte proliferation and differentiation defects rather than being purely haemodynamic,
    and the disease is genetically heterogeneous and multigenic rather than attributable to one
    locus. Similar but milder defects in the right ventricle in these models are the animal
    counterpart of the late systemic right ventricular failure seen in patients.
  experimental_model_type: OTHER
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  modeled_mechanisms:
  - target: Impaired cardiomyocyte proliferation and differentiation
    description: >
      The models demonstrate cell-autonomous proliferation and differentiation defects underlying
      the hypoplasia.
  - target: Genetic lesion affecting cardiac growth or valvulogenesis
    description: >
      Eight independent lines establish the multigenic architecture the trigger node describes.
  publication: PMID:29569026
  evidence:
  - reference: PMID:29569026
    reference_title: "The Genetic Landscape of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Analysis of 8 independent HLHS mouse lines showed HLHS is genetically heterogeneous and multigenic in etiology."
    explanation: >-
      Establishes the multigenic architecture from independently derived lines rather than from a
      single mutant.
  - reference: PMID:29569026
    reference_title: "The Genetic Landscape of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The findings of similar defects of lesser severity in the right ventricle suggest this could contribute to the heart failure risks in surgically palliated HLHS patients."
    explanation: >-
      Provides the model-organism counterpart of the recessive-variant finding in patients, that
      the right ventricle is not a normal chamber pressed into abnormal service but is itself
      affected.

diagnosis:
- name: Fetal echocardiography
  description: >
    Prenatal diagnosis, which for this disease is not simply earlier diagnosis but a different
    clinical situation. It permits delivery at a surgical centre with prostaglandin ready, and in
    the evolving form it permits serial assessment and the possibility of fetal intervention.

- name: Newborn pulse oximetry screening
  description: >
    Detection of the ductal-dependent circulation before collapse by measuring saturation in a
    well infant. It works here because the mixing lesion produces measurable desaturation before
    it produces symptoms, and it is the intervention that most changes whether a child presents
    electively or in shock.

- name: Postnatal echocardiography
  description: >
    Confirms the anatomy and, critically, the adequacy of the interatrial communication, since a
    restrictive atrial septum obstructs pulmonary venous return and constitutes an emergency
    separate from the ductal one.

- name: Genetic and cytogenetic testing
  description: >
    Chromosomal analysis and sequencing, offered because a minority of cases occur within a
    cytogenetic syndrome and because family clustering establishes heritability. What testing
    can deliver here is bounded in an unusual way. It reliably identifies the syndromic minority,
    and it usually does not identify a causal variant in the rest, not because the sequencing is
    inadequate but because the inheritance is not the kind a single variant explains. Counselling
    therefore has to distinguish a syndromic diagnosis, which carries its own recurrence risk and
    extracardiac surveillance, from a negative result, which does not mean the disease is
    non-genetic.
  evidence:
  - reference: PMID:38884762
    reference_title: "Human Genetics of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The implication of this conclusion is that researchers must move beyond the expectation that a single disease-causing variant can be found."
    explanation: >-
      Supports the limitation this diagnostic entry records, that a negative sequencing result is
      the expected outcome rather than an informative exclusion.

progression:
- phase: Mid-gestation
  notes: >
    In the evolving form, critical aortic stenosis is present while the left ventricle is still
    of adequate size. This is the only window in which the disease can be modified rather than
    palliated.

- phase: Term
  notes: >
    Left heart structures are established as hypoplastic or atretic and the circulation is
    committed to ductal dependence.

- phase: First days of life
  notes: >
    The duct closes and systemic perfusion fails without prostaglandin. This is the point at which
    the disease was uniformly fatal before surgical palliation.

- phase: Staged palliation through childhood
  notes: >
    Three operations over the first few years convert the parallel circulation to a series
    circulation with a systemic right ventricle and passive pulmonary flow.

- phase: Adult survivorship
  notes: >
    Fewer than a third are alive without transplantation at thirty-five years, and the figure has
    not improved across recent surgical eras. Outcome is heterogeneous, with a subset reporting
    good to excellent health.
  evidence:
  - reference: PMID:40533128
    reference_title: "Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this cohort of newborns undergoing staged reconstructive surgery for HLHS, fewer than one-third are alive without a transplant at 35 years of age. Survival has not improved in recent years."
    explanation: >-
      Supports both the long-term survival figure and the plateau, in a cohort of over two
      thousand neonates spanning four decades.

differential_diagnoses:
- name: Critical aortic stenosis with an adequate left ventricle
  description: >
    The distinction that matters most before birth, because it separates a fetus who might be
    offered valvuloplasty and a biventricular outcome from one already committed to single
    ventricle palliation. It is a judgement about a spectrum rather than a categorical difference,
    which is why the evolving form is curated as a subtype here.

- name: Other functionally univentricular hearts
  description: >
    Tricuspid atresia, double inlet left ventricle, and unbalanced atrioventricular septal defect
    all end in the same Fontan pathway. They are worth distinguishing because outcomes differ, and
    this disease does worse than the others despite the same operation and the same systemic right
    ventricle.

- name: Neonatal sepsis
  description: >
    Shares shock, acidosis, and poor perfusion in a previously well newborn, and is the diagnosis
    usually reached first in an infant who collapses on ductal closure without a prenatal
    diagnosis. Fluid resuscitation and antibiotics do not help, and the delay is consequential.

prevalence:
- population: Newborns with congenital heart disease
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >
    An estimated three percent of newborns with congenital heart disease develop this condition.
    That is a proportion of a diseased population rather than a population rate, so it is recorded
    in notes with its own evidence rather than normalised into a rate per hundred thousand, which
    would misrepresent the denominator.
  evidence:
  - reference: PMID:40386366
    reference_title: "Hypoplastic left heart syndrome-a scoping review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An estimated 3% of all newborns with congenital heart disease develop hypoplastic left heart syndrome (HLHS), making it a prominent cause of mortality in this group if surgical procedures or a heart transplant are not implemented."
    explanation: >-
      Gives the proportion among newborns with congenital heart disease, which is the denominator
      this record uses.

discussions:
- discussion_id: what_starts_the_disease
  kind: CONTROVERSY
  status: OPEN
  prompt: >
    Does hypoplastic left heart syndrome begin with a myocardial defect, with a valvar
    obstruction, or with something that produces both?
  rationale: >
    This is the field's central unsettled question and it is unusual in being a dispute about the
    kind of cause rather than the identity of one. The flow theory has the strongest human
    support, since relieving an obstruction in mid-gestation lets left-sided structures grow. The
    intrinsic-defect account has the strongest cellular support, since the first genetic mouse
    model showed proliferation and differentiation defects and a second, independent model in a
    different organism agreed. The reconciling position, that a myocardial defect impairs pump
    function and the resulting flow deficit produces the structural lesion, is supported by a
    tissue-restricted rescue but rests on one model organism with a heart that has no left
    ventricle. The practical stake is which fetuses can be helped, since only the mechanical
    component is currently addressable.
  attaches_to:
  - "pathophysiology#Reduced flow through the left heart"
  - "pathophysiology#Impaired cardiomyocyte proliferation and differentiation"
  evidence:
  - reference: PMID:42200818
    reference_title: "Is There a Unified Etiology of Hypoplastic Left Heart Syndrome? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "No single hypothesis has fully explained how HLHS is initiated, progresses, and presents with the clinical conditions that are encountered by cardiac surgeons and cardiologists."
    explanation: >-
      The review's own verdict, which is the reason this entry curates three hypothesis groups
      rather than selecting one. Evidence source is OTHER because it is a review.
  proposed_experiments:
  - experiment_id: exp_genotype_stratified_fetal_intervention
    name: Genotype-stratified analysis of fetal valvuloplasty response
    description: >
      Sequence a cohort undergoing fetal aortic valvuloplasty and test whether achieving a
      biventricular circulation is predicted by the absence of variants in myocardial growth and
      sarcomeric genes. The three hypotheses make different predictions. Pure flow theory predicts
      no genotype effect, the intrinsic-defect model predicts poor response regardless, and the
      reconciling model predicts response is graded by how much of the pump deficit is mechanical.

- discussion_id: is_late_right_ventricular_failure_a_myopathy
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >
    Is failure of the systemic right ventricle after palliation an afterload consequence, an
    expression of the same myocardial defect that arrested the left ventricle, or both?
  rationale: >
    The default assumption is mechanical, that a chamber built for low pressure eventually fails
    under systemic load. Two independent observations complicate it. Patients with this disease
    fare substantially worse after Fontan palliation than patients with other anatomies who have
    the same systemic right ventricle and the same operation, which points at something in the
    disease rather than in the load. And recessive sarcomeric variants were found in patients who
    developed late right ventricular dysfunction, with the authors framing it as one molecular
    basis expressed as developmental arrest on the left and latent myopathy on the right. If that
    is general, then some patients are destined to fail regardless of haemodynamic optimisation,
    and identifying them prospectively would change transplant listing rather than only prognosis.
  attaches_to:
  - "pathophysiology#Systemic right ventricle after staged palliation"
  evidence:
  - reference: PMID:39604028
    reference_title: "Cardiovascular Outcomes Associated With Hypoplastic Left Heart Syndrome Versus Other Types of Single Right Ventricle: A Multicenter Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The composite outcome occurred in 7.1 versus 2.1 cases per 100 person-years in patients with HLHS versus non-HLHS (P<0.0001)."
    explanation: >-
      Isolates the disease from the operation and the ventricular morphology by comparing against
      other single-ventricle anatomies, which is what makes the excess risk informative about
      intrinsic myocardium.
  - reference: PMID:26085007
    reference_title: "Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings implicate a shared molecular basis for the developmental arrest and latent myopathy of left and right ventricles, respectively."
    explanation: >-
      States the hypothesis in the authors' own terms. Graded PARTIAL because it rests on two
      patients and cannot establish how much of the population-level excess risk it explains.
  proposed_experiments:
  - experiment_id: exp_sarcomeric_genotype_and_fontan_rv_function
    name: Sarcomeric genotype and systemic right ventricular trajectory
    description: >
      In a multicentre Fontan cohort, test whether rare sarcomeric and cardiomyopathy-gene variant
      burden predicts the rate of decline in systemic right ventricular ejection fraction
      independently of haemodynamic variables, using other single-ventricle anatomies as the
      comparator group.

- discussion_id: model_systems_lack_a_left_ventricle
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >
    Can a disease defined by the failure of one specific chamber to grow be modelled in organisms
    whose hearts are not built the same way?
  rationale: >
    The two model systems that carry most of the mechanistic weight in this entry both have an
    anatomical mismatch with the disease. The zebrafish heart has a single ventricle and no left
    heart in the mammalian sense, so a model of RBFOX2 loss can show that structural deficits are
    downstream of pump function without showing that the human left ventricle behaves the same
    way. The mouse has the right anatomy but reaches the phenotype through mutations that are not
    the ones most human patients carry, and the human genetic architecture includes
    lower-penetrance and common variation that single-locus mouse lines do not represent. This is
    a fidelity question rather than an absence of evidence, since the experiments themselves are
    strong. What is uncertain is how far a conclusion about causal order in a two-chambered heart
    transfers to a four-chambered one.
  attaches_to:
  - "pathophysiology#Impaired cardiomyocyte proliferation and differentiation"
  - "pathophysiology#Reduced flow through the left heart"
  evidence:
  - reference: PMID:36198703
    reference_title: "Intrinsic myocardial defects underlie an Rbfox-deficient zebrafish model of hypoplastic left heart syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we report that zebrafish lacking two orthologs of the RNA binding protein RBFOX2, a gene linked to HLHS in humans, display cardiovascular defects overlapping those in HLHS patients including ventricular, valve, and aortic deficiencies."
    explanation: >-
      The word overlapping is doing the work. The defects correspond rather than being identical,
      which is the mismatch this discussion is about. Graded PARTIAL for that reason.
  - reference: PMID:36286267
    reference_title: "Considering the Genetic Architecture of Hypoplastic Left Heart Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, unlike classical Mendelian disorders where a relatively small number of genes are largely determinative of the occurrence and severity of the disease, the picture in HLHS is complex."
    explanation: >-
      Supports the second half of the mismatch, that the human genetic architecture is not the
      single-locus architecture the mouse lines instantiate.
  proposed_experiments:
  - experiment_id: exp_human_cardiac_organoid_flow_manipulation
    name: Flow manipulation in patient-derived human cardiac organoids
    description: >
      Use patient-derived induced pluripotent stem cell cardiac organoids or chamber-forming
      cardioids carrying HLHS-associated variants, with controlled perfusion, to test whether the
      growth deficit is cell-autonomous, flow-dependent, or both in human tissue with human
      genetic background, closing the anatomical and genetic gaps the animal models leave open.

notes: >
  Scope. This entry curates hypoplastic left heart syndrome including the palliated circulation as
  a disease state, on the reasoning that staged palliation does not repair the lesion and that the
  late complications belong to the reconstructed physiology. The neurodevelopmental, hepatic, and
  lymphatic sequelae of the Fontan circulation are consequences of that physiology and are named
  in the prose without being curated as nodes, since this entry cites no evidence for them.

  Module conformance. None is declared. The obvious candidate,
  cardiomyopathy_maladaptive_remodeling, describes an insult to a normally formed heart followed
  by neurohormonal activation and ventricular remodelling. The systemic right ventricle here is a
  congenitally normal chamber placed in an abnormal circulation, and the entry's own argument is
  that its failure may be partly a myopathy present from the start rather than remodelling in
  response to load. Declaring conformance would assert the mechanism the entry is careful to leave
  open. If the afterload arm were curated separately with its own evidence it would be a
  legitimate conformance target.

  Competing hypotheses. Three mechanistic_hypotheses groups are curated rather than one, because
  the disagreement about this disease is real and current, and because the causal edges genuinely
  differ between the models rather than merely being described differently. Edges opt into
  hypothesis groups so a reader can see which parts of the pathograph each model owns. The
  reconciling group is marked EMERGING and rests on a single model organism.

  Deep-research provenance. Curated from a claude_code deep-research report treated as leads only.
  Its citations were reliable, with all ten identifiers resolving to the papers claimed and
  correctly characterised. Its ontology suggestions were less so. UBERON:0002094 was offered for
  left ventricle and is the interventricular septum, and UBERON:0002078 was offered for right
  ventricle and is the right cardiac atrium. The correct terms used here are UBERON:0002084 and
  UBERON:0002080, with UBERON:0002135 for the mitral valve, which the report did not supply.

  NEC preflight returned SKIP, since MONDO records no causal gene. The manual fallback passed. The
  report's OMIM identifiers 241550 and 614435 are the two designated subtypes of this disease and
  190198 and 600584 are NOTCH1 and NKX2-5, and the top gene mentions, NOTCH1, MYH6, NKX2-5,
  SAP130, and HAND1, are all genuine loci for it. SAP130 is discussed in this entry's prose as the
  gene behind the first mouse model but is not curated as a genetic entry, because the evidence
  cited here is about the mouse lines collectively rather than about that locus in patients.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Hypoplastic Left Heart Syndrome (HLHS) — Comprehensive Disease Characteristics Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 33 citations 2026-08-10T03:49:41.007038

Hypoplastic Left Heart Syndrome (HLHS) — Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect (CHD) characterized by underdevelopment of left-sided cardiac structures — the left ventricle, mitral valve, aortic valve, and ascending aorta/aortic arch — such that the left heart cannot support systemic circulation. It is uniformly fatal without intervention in the neonatal period, historically among the leading causes of death from a single birth defect in the first year of life. HLHS represents the most severe end of a spectrum of left heart underdevelopment/obstruction lesions (sometimes grouped with critical aortic stenosis and other single-ventricle physiologies) (StatPearls – Hypoplastic Left Heart Syndrome; Sergi, Transl Pediatr 2025 scoping review, PMID:40386366).

Key identifiers: - OMIM: 241550 (Hypoplastic Left Heart Syndrome 1, HLHS1) and 614435 (Hypoplastic Left Heart Syndrome 2, HLHS2 — caused by NKX2-5 mutation) (OMIM 241550; OMIM 614435) - Orphanet: ORPHA:2248 (Orphanet: Hypoplastic left heart syndrome) - MONDO: MONDO:0004933 - ICD-10-CM: Q23.4 - ICD-11: LA61.0 (or equivalent congenital malformation of left ventricle code) - MeSH: D016360 (Hypoplastic Left Heart Syndrome)

Synonyms / alternative names: HLHS; hypoplastic left heart complex; aortic atresia/mitral atresia syndrome; hypoplasia of left heart; Noonan-Reid syndrome (historical, not current usage); "underdevelopment of the left heart."

Evidence base note: Information on HLHS in the literature is derived from a mix of aggregated disease-level resources (OMIM, Orphanet, national birth-defect registries) and individual patient-level data (single- and multi-center surgical outcome cohorts, exome-sequencing case series, fetal echocardiography case series, and disease registries such as the Pediatric Cardiac Genomics Consortium and the Single Ventricle Reconstruction [SVR] trial cohort). Most genetic and mechanistic claims derive from small clinical cohorts (tens to low hundreds of probands) combined with animal-model and iPSC data, reflecting the rarity of the condition and its genetic heterogeneity.

2. Etiology

Disease causal factors

HLHS is now understood as a developmentally and genetically heterogeneous "final common pathway" phenotype rather than a single-gene disorder. Two broad, non-mutually-exclusive models of pathogenesis are debated in current literature (PMID:42200818, Pathophysiology 2026, "Is There a Unified Etiology of HLHS? Evaluating Genetic, Structural, and Hemodynamic Models of Disease Initiation"):

  1. Primary genetic/developmental model — an intrinsic defect in cardiomyocyte proliferation, differentiation, or endocardial-to-mesenchymal signaling causes primary hypoplasia of left heart structures.
  2. Flow (hemodynamic) theory — an initiating lesion (e.g., mitral or aortic valve stenosis/atresia) reduces antegrade flow across the left heart in mid-gestation; per Reynolds/shear-stress-dependent growth ("no-flow, no-grow"), reduced flow secondarily arrests growth of the left ventricle, aortic valve, and ascending aorta. This model is supported by serial fetal echocardiography documenting progression from isolated critical aortic stenosis in mid-gestation to frank HLHS by term, and by the partial rescue of biventricular growth after fetal aortic valvuloplasty relieves the flow obstruction (PMID:25052401).

Neither model alone fully explains the pathology; the flow theory does not adequately explain endocardial fibroelastosis (EFE) or the histological/molecular abnormalities seen in even mild-flow-disturbance cases, motivating combined genetic-plus-hemodynamic ("two-hit") models.

Genetic risk factors

  • Monogenic/familial forms (minority of cases): pathogenic variants in NKX2-5 (OMIM 614435, HLHS2; chromosome 5q35.1), NOTCH1 (9q34.3 — both germline dominant and compound-heterozygous recessive forms reported; PMID:28608148), GJA1 (connexin-43; 6q22 — missense substitutions identified in pediatric HLHS transplant recipients), HAND1 (5q33, including somatic/postzygotic mutations found in cardiac tissue), MYH6 (α-myosin heavy chain, 14q11.2 — rare damaging variants enriched in ~10% of HLHS probands, both dominant and recessive patterns, associated with reduced transplant-free survival; PMID:26085007; PMC5206387), ZIC3, MCTP2.
  • Oligogenic/polygenic burden: whole-exome sequencing of HLHS trios (Pediatric Cardiac Genomics Consortium, ~330 coding/splicing candidate variants identified across probands) shows no single shared causal variant across most patients — supporting a model of genetic heterogeneity with variable, possibly additive, contributions from multiple CHD-associated genes including AXIN1, BMP2, COL6A2, GATA4, GATA5, GDF1, MESP1, NFATC1, NKX2-6, PCSK9, TBX1, TBX18, and TBX20 (PMC9604382, "Considering the Genetic Architecture of Hypoplastic Left Heart Syndrome").
  • Chromosomal/syndromic causes: HLHS occurs in association with recognized chromosomal syndromes in an estimated 3–20% of cases, most commonly Turner syndrome (45,X), trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), Jacobsen syndrome (terminal 11q deletion) — notably HLHS occurs in up to ~10% of Jacobsen syndrome patients vs. ~0.2% in the general population (PMC9864704, "Jacobsen Syndrome with HLHS: Outcome after Cardiac Transplantation") — and less commonly Smith–Lemli–Opitz syndrome, Holt–Oram syndrome, and partial trisomy 9.
  • Family recurrence risk: empiric recurrence risk in siblings of an HLHS proband is elevated (~2–4× population risk, historically cited around 2–4%), and first-degree relatives show increased rates of the broader "left ventricular outflow tract obstruction (LVOTO)" spectrum (bicuspid aortic valve, coarctation), consistent with variable expressivity of shared genetic susceptibility.

Environmental risk factors

Environmental contributions are less well characterized than in some other CHDs, but epidemiologic studies of the broader CHD/LVOTO spectrum implicate: - Maternal pregestational diabetes mellitus - Maternal obesity - Certain maternal medication exposures (e.g., some anticonvulsants) and possibly maternal febrile illness in the first trimester - Advanced or very young maternal age (mixed evidence) - Periconceptional folic acid deficiency (protective factor when adequate; see below)

Protective factors

  • Genetic: no well-established protective alleles are specifically described for HLHS; population variant databases (gnomAD) are used to filter candidate pathogenic variants by rarity, but specific protective modifier alleles have not been robustly identified.
  • Environmental: periconceptional folic acid/multivitamin supplementation is associated with reduced risk of CHD broadly (evidence strongest for outflow-tract defects), and is presumed protective for HLHS by extension, though HLHS-specific data are limited.

Gene-environment interactions

Direct gene-environment interaction data specific to HLHS are sparse. The leading conceptual model is a "two-hit" or multi-hit hypothesis in which an underlying genetic susceptibility (e.g., in a proliferation, ciliary, or Notch-pathway gene) combines with a hemodynamic/flow perturbation (itself potentially influenced by maternal-fetal circulatory factors) to produce the full HLHS phenotype, rather than either factor alone being sufficient. This is analogous to the two-locus requirement demonstrated in the murine Ohia model (see Section 15).

Suggested ontology terms: MONDO:0004933 (HLHS); HP:0031335 (Abnormal aortic valve morphology); GO:0003007 (heart morphogenesis); GO:0003231 (cardiac ventricle development).

3. Phenotypes

HLHS phenotypes span cardiac structural anomalies (present from birth, essentially fully penetrant by definition), physiologic/circulatory consequences of ductal-dependent systemic circulation, and postnatal/post-surgical complications.

Core structural/anatomic phenotypes (clinical signs — congenital onset, present at birth, generally non-progressive as an anatomic entity though physiologically evolving)

Phenotype Frequency Suggested HPO term
Mitral valve atresia or severe hypoplasia/stenosis Frequent, near-universal in classic HLHS HP:0011623 (Mitral atresia) / HP:0001633 (Mitral stenosis)
Aortic valve atresia or severe stenosis Frequent, near-universal HP:0011541 (Aortic valve atresia) / HP:0001650 (Aortic valve stenosis)
Hypoplastic left ventricle Obligate HP:0031624 (Hypoplastic left heart) / HP:0004268 (Hypoplastic left ventricle, if available)
Hypoplastic ascending aorta / aortic arch Frequent HP:0005107 (Hypoplasia of the aorta)
Endocardial fibroelastosis (left ventricular endocardium) Variable, present in a subset, often correlates with residual antegrade flow HP:0034194 (Endocardial fibroelastosis) if present in ontology, else free text
Atrial septal defect / restrictive foramen ovale Frequent (often obligate for postnatal mixing) HP:0001631 (Atrial septal defect)
Patent ductus arteriosus (physiologically obligate for survival) Obligate pre-intervention HP:0001643 (Patent ductus arteriosus)
Retrograde aortic arch flow (fetal/prenatal) Frequent in classic variant —

Clinical presentation / laboratory-lab-adjacent phenotypes (postnatal, onset within hours to days of birth as the ductus arteriosus closes)

  • Cyanosis (variable — may be subtle if atrial mixing is adequate; profound if restrictive atrial septum) — HP:0000961
  • Circulatory shock / cardiogenic shock as PDA closes — HP:0008551 or generic shock term
  • Poor feeding, lethargy, tachypnea, respiratory distress — HP:0011968 (Feeding difficulties), HP:0002094 (Dyspnea)
  • Weak or absent peripheral pulses, differential cyanosis
  • Metabolic acidosis (laboratory abnormality) secondary to systemic hypoperfusion
  • Hypoglycemia, secondary to poor perfusion/feeding
  • Pulmonary overcirculation (if ductus remains patent and pulmonary vascular resistance falls) leading to pulmonary edema

Age of onset / severity / progression

  • Onset: congenital, almost always diagnosed prenatally (2nd–3rd trimester fetal echocardiogram) in current-era high-income-country practice, or in the immediate neonatal period as the ductus arteriosus closes (typically within the first 24–48 hours of life if undiagnosed prenatally).
  • Severity: HLHS is intrinsically severe/lethal without intervention; within the diagnosis there is a spectrum (mitral stenosis/aortic atresia [MS/AA] vs. mitral atresia/aortic atresia [MA/AA] vs. mitral stenosis/aortic stenosis [MS/AS]) that correlates with degree of left ventricular hypoplasia, presence/severity of EFE, and postnatal outcome — the MS/AA and MA/AA subtypes generally carry higher operative risk than milder MS/AS variants.
  • Progression: the anatomic lesion itself is largely fixed at birth, but the physiologic course is progressive if untreated (ductal closure → cardiovascular collapse → death, typically within days).

Quality of life impact

Survivors of staged palliation show measurably lower health-related quality of life (HRQOL) than healthy peers and than children with other chronic illnesses across physical, psychosocial, emotional, social, and school-functioning domains, with the proportion of "at-risk"/impaired HRQOL increasing over childhood (e.g., total domain "at risk" 28%→39% over a longitudinal cohort) (PMID:28847316, Cardiol Young). Neurodevelopmental dysfunction correlates strongly with worse self-reported HRQOL. Family-level dysfunction is reported in roughly a quarter of families despite overall family function often exceeding published norms.

Suggested HPO terms (summary): HP:0011623, HP:0011541, HP:0031624, HP:0005107, HP:0001631, HP:0001643, HP:0000961, HP:0002094, HP:0001943 (hypoglycemia).

4. Genetic/Molecular Information

Causal genes (monogenic/major-effect)

Gene HGNC/OMIM Role Variant classification notes
NKX2-5 5q35.1; OMIM 600584 (gene), 614435 (HLHS2) Cardiac transcription factor, required for cardiac chamber specification Missense/LOF variants reported causal in familial HLHS2
NOTCH1 9q34.3; OMIM 190198 Notch signaling, valvulogenesis, ventricular trabeculation, endocardial cushion/AV canal formation Germline dominant frameshift/stop-gain (PMID:28608148) and compound-heterozygous recessive variants (Springer 2015, "Compound heterozygous NOTCH1 mutations...") reported; hypomorphic expression alters cardiomyocyte architecture in iPSC models (bioRxiv 2024/2025)
GJA1 (connexin-43) 6q22.31 Gap-junction protein, cardiac conduction and morphogenesis Missense substitutions found in HLHS transplant recipients (Dasgupta et al.)
HAND1 5q33.2 bHLH transcription factor, left ventricular chamber morphogenesis Includes somatic (postzygotic) mutations detected in cardiac tissue specifically
MYH6 14q11.2 Cardiac α-myosin heavy chain, sarcomere contractile protein Damaging variants (missense, in-frame deletion, premature stop, de novo, compound heterozygous) enriched in ~10% of HLHS cases (PMID:26085007); associated with reduced transplant-free survival and atrial dysfunction (PMC11593362)
ZIC3 Xq26.3 Left-right axis determination Implicated in laterality-associated HLHS cases
MCTP2 15q26.2 Calcium-binding transmembrane protein, implicated by CNV/exome studies Candidate gene
SAP130, PCDHA9 Human orthologs of Ohia mouse genes Chromatin remodeling (SAP130, part of Sin3A/HDAC complex) and protocadherin cell-adhesion signaling Identified via mouse forward-genetic screen; human relevance under study

Additional genes recurrently implicated across cohort exome studies (each accounting for a small fraction of cases): AXIN1, BMP2, COL6A2, GATA4, GATA5, GDF1, MESP1, NFATC1, NKX2-6, PCSK9, TBX1, TBX18, TBX20 (PMC9604382).

Variant classification and population frequency

  • Per ACMG/AMP framework, most HLHS-associated variants identified to date are classified pathogenic/likely pathogenic in a minority of cases with clear familial segregation (e.g., NOTCH1, NKX2-5 dominant families) and variants of uncertain significance (VUS) in the majority of sporadic cases, given incomplete penetrance and genetic heterogeneity.
  • Rare variant burden analyses show enrichment of predicted-damaging, rare (gnomAD allele frequency typically <0.1–1%) variants in HLHS probands relative to population controls, consistent with a rare-variant, multi-gene architecture rather than common-variant (GWAS-style) risk.
  • Somatic/postzygotic mosaicism: HAND1 somatic mutations detected specifically in affected cardiac tissue (not blood) implicate postzygotic mosaicism as a contributing mechanism in at least some sporadic cases — an important methodological point, since blood-based exome sequencing alone would miss these variants.

Functional consequences

  • Loss-of-function / haploinsufficiency: NOTCH1, NKX2-5 — impairing normal cardiomyocyte proliferation and endocardial cushion/valve formation.
  • Dominant-negative or hypomorphic effects: hypomorphic NOTCH1 expression (rather than complete null) alters cardiomyocyte cellular architecture in HLHS-derived iPSC models, suggesting partial pathway disruption rather than complete loss is sufficient to produce disease in the sensitized developing heart.
  • Gain/dysregulation of fibrotic signaling: endothelial-to-mesenchymal transition (EndMT) has been identified as the mechanism underlying endocardial fibroelastosis formation in HLHS hearts, representing a downstream, convergent molecular consequence regardless of the specific upstream causal variant.

Modifier genes

MYH6 variant status has been shown to modify outcome (reduced transplant-free survival) rather than acting as a primary cause in isolation in all carriers, suggesting a modifier role in some genetic backgrounds; the broader multi-gene co-occurrence pattern (e.g., patients carrying variants across AXIN1, BMP2, GATA4/5, TBX1/18/20 simultaneously) is itself consistent with an oligogenic modifier model rather than single fully penetrant drivers.

Epigenetic information

Limited HLHS-specific epigenomic data exist in the literature relative to the volume of exome/genome work; EndMT (the EFE mechanism) is regulated in other cardiovascular fibrosis contexts by TGF-β/Smad and chromatin-modifying programs, and SAP130 (Ohia model) is itself a component of the Sin3A-HDAC histone-deacetylase corepressor complex, directly linking one of the strongest HLHS mouse candidate genes to chromatin regulation of cardiac developmental gene expression.

Chromosomal abnormalities

See Section 2 (Turner 45,X; trisomy 13; trisomy 18; Jacobsen 11q terminal deletion) — DECIPHER and ClinVar catalog these recurrent CNV/aneuploidy associations; chromosomal microarray and karyotype are standard first-line genetic tests in a new HLHS diagnosis (see Section 10).

Suggested ontology terms: hgnc:7876 (NKX2-5), hgnc:7881 (NOTCH1), hgnc:4274 (GJA1), hgnc:4811 (HAND1), hgnc:7576 (MYH6); GO:0003007 (heart morphogenesis); GO:0007219 (Notch signaling pathway); GO:0001837 (epithelial to mesenchymal transition).

5. Environmental Information

  • Environmental/toxin factors: Data specific to HLHS (vs. CHD broadly) are limited. Broader CHD literature (CTD, epidemiologic studies) implicates maternal exposure to certain organic solvents, some pesticides, and air pollution (PM2.5) as modestly associated with CHD risk generally; specificity to HLHS is not well established.
  • Lifestyle factors: Maternal pregestational diabetes and obesity are the most consistently reported maternal risk factors across the CHD/LVOTO literature; maternal smoking and alcohol use show inconsistent associations with HLHS specifically.
  • Infectious agents: No infectious agent is established as a direct cause of HLHS. Maternal febrile illness/rubella exposure in the first trimester is a classical general CHD risk factor (particularly for PDA and pulmonary stenosis in congenital rubella syndrome) but is not specifically linked to HLHS.

Given the paucity of HLHS-specific environmental epidemiology, curators should treat environmental risk-factor claims as extrapolated from the broader CHD/LVOTO literature unless a HLHS-specific citation is found.

6. Mechanism / Pathophysiology

Causal chain overview

  1. Initiating lesion — either (a) an intrinsic genetic defect in cardiomyocyte proliferation/differentiation or valvulogenesis (e.g., NOTCH1, NKX2-5, MYH6, SAP130 dysfunction), or (b) a primary mechanical/flow obstruction at the mitral or aortic valve (e.g., evolving critical aortic stenosis) — occurring in mid-gestation.
  2. Reduced left heart flow — whichever the primary trigger, flow across the mitral valve and outflow through the aortic valve/ascending aorta becomes markedly reduced.
  3. Impaired shear-stress-dependent growth signaling — reduced flow removes the mechanotransductive stimulus normally required for proportionate chamber and valve growth ("no-flow, no-grow" hypothesis), while intrinsic transcriptional/proliferative defects independently limit myocardial growth.
  4. Endothelial-to-mesenchymal transition (EndMT) and endocardial fibroelastosis — abnormal endocardial shear/genetic signaling drives EndMT, producing pathological deposition of fibroelastic tissue lining the hypoplastic LV cavity, further restricting compliance and inflow.
  5. Myocardial disarray and cardiomyocyte-fibroblast imbalance — histopathology shows disorganized myocyte architecture and a shifted fibroblast:cardiomyocyte ratio, directly contributing to the small, non-compliant, poorly contractile left ventricle.
  6. Progressive left heart hypoplasia — by term, the mitral valve, LV, aortic valve, and ascending aorta/arch are all markedly undersized/atretic, with the ascending aorta functioning only as a retrograde-perfused conduit to the coronary arteries (via the ductus arteriosus and aortic arch) in classic aortic-atresia HLHS.
  7. Obligate right-heart/ductal-dependent physiology at birth — after birth, systemic circulation is entirely dependent on right-to-left ductal shunting (PDA) for systemic (and often, in aortic atresia, coronary) perfusion, and on an unrestrictive interatrial communication for pulmonary venous return to reach the systemic circulation; the right ventricle serves as the sole functional systemic ventricle.
  8. Clinical decompensation — as the ductus arteriosus physiologically closes postnatally (typically 24–72 hours), systemic and/or coronary perfusion collapses, producing shock, acidosis, and death if untreated.

Upstream vs. downstream

  • Upstream: genetic lesions in transcription factors/signaling genes (NOTCH1, NKX2-5, GATA4/5, TBX genes) and/or primary valvular obstruction.
  • Midstream: reduced intracardiac flow, impaired cardiomyocyte proliferation, EndMT.
  • Downstream: structural hypoplasia of LV/mitral/aortic valve/aorta, EFE, and — postnatally — ductal-dependent circulatory physiology and its complications (shock, end-organ hypoperfusion).

Molecular pathways

  • NOTCH signaling (GO:0007219) — valvulogenesis, endocardial cushion formation, ventricular trabeculation; central pathway implicated by NOTCH1 variants and hypomorphic-expression iPSC models.
  • NKX2-5/GATA4/TBX5 cardiac transcriptional network — chamber specification and septation.
  • TGF-β/Smad signaling — implicated in EndMT-driven endocardial fibroelastosis.
  • Sin3A-HDAC chromatin corepressor complex (via SAP130) — implicated by the Ohia mouse model, linking chromatin regulation to left heart growth.
  • Protocadherin (PCDHA9) cell-adhesion signaling — implicated in aortic/aortic-valve component of the Ohia digenic phenotype.

Cellular processes

  • Decreased cardiomyocyte proliferation and increased apoptosis (demonstrated in Ohia SAP130/PCDHA9 double-mutant mice)
  • Altered mitochondrial maturation in cardiomyocytes
  • Endothelial-to-mesenchymal transition (EndMT) in endocardium
  • Myocardial disarray / disorganized sarcomeric architecture (MYH6-related)

Protein dysfunction

  • MYH6 (α-myosin heavy chain) missense/truncating variants alter sarcomeric contractile function — iPSC-cardiomyocytes carrying an MYH6 head-domain variant show measurably altered contractility (PMC7324479).
  • NOTCH1 hypomorphic expression alters cardiomyocyte cellular architecture in iPSC-CM models.

Tissue damage mechanisms

  • Chronic pressure/volume mismatch and reduced coronary perfusion (especially in aortic atresia, where coronary flow is retrograde via the ductus/aortic arch) contribute to subendocardial ischemia and further myocardial injury in the hypoplastic LV.
  • EFE itself is a fibrotic tissue-damage response to abnormal flow/shear stress.

Molecular profiling / advanced technologies

  • Transcriptomics: iPSC-cardiomyocyte models (NOTCH1-null, MYH6-variant) show altered cardiac proliferative gene programs.
  • Single-cell/functional genomics: an eLife 2025 study ("Functional analysis across model systems implicates ribosomal proteins in growth and proliferation defects associated with HLHS") extends the candidate gene set to ribosomal protein genes affecting growth/proliferation across zebrafish, mouse, and human iPSC systems.
  • Comparative model systems: In Vivo and In Vitro modeling reviews (PMC11538128, Curr Cardiol Rep 2024/2025) summarize convergent iPSC-CM, zebrafish, and mouse (Ohia) approaches.

Suggested GO/CL terms: GO:0007219 (Notch signaling pathway), GO:0003231 (cardiac ventricle development), GO:0003170 (heart valve development), GO:0001837 (EMT), GO:0006915 (apoptotic process), CL:0000746 (cardiac muscle cell / cardiomyocyte), CL:0000115 (endothelial cell), CL:0000057 (fibroblast).

7. Anatomical Structures Affected

Organ level

  • Primary: heart — specifically left ventricle, mitral valve, aortic valve, ascending aorta, aortic arch.
  • Secondary/complication-related: right ventricle (chronic systemic-ventricle pressure/volume overload, eventual dysfunction), lungs (pulmonary overcirculation or, post-Fontan, passive pulmonary blood flow and its long-term hepatic/lymphatic consequences), liver (Fontan-associated liver disease from chronically elevated systemic venous pressure), brain (neurodevelopmental sequelae from perioperative hypoxia/hypoperfusion and possible in-utero cerebral blood flow alterations), gastrointestinal tract (protein-losing enteropathy as a late Fontan complication).
  • Body systems: cardiovascular (primary); neurological (secondary, developmental); hepatic (secondary, chronic); lymphatic (secondary — plastic bronchitis, protein-losing enteropathy).

Suggested UBERON terms: UBERON:0002094 (left ventricle), UBERON:0001917 (mitral valve), UBERON:0002137 (aortic valve), UBERON:0001496 (ascending aorta), UBERON:0001508 (aortic arch), UBERON:0002078 (right ventricle).

Tissue and cell level

  • Endocardium (site of EFE and EndMT) — CL:0002350 (endocardial cell) / CL:0000115 (endothelial cell)
  • Cardiac myocytes (myocardial disarray, reduced proliferation) — CL:0000746
  • Cardiac fibroblasts (imbalance with cardiomyocytes contributing to hypoplasia) — CL:0000057
  • Valve interstitial/endothelial cells in the atretic/stenotic mitral and aortic valves

Subcellular level

  • Sarcomere/myofilament apparatus (MYH6-related dysfunction) — GO:0030017 (sarcomere)
  • Mitochondria (altered maturation in HLHS model cardiomyocytes) — GO:0005739
  • Cell-cell junctions (GJA1/connexin-43 gap junctions) — GO:0005921 (gap junction)

Localization

  • Left-sided cardiac structures — generally not "unilateral" in the laterality sense but confined to the left heart chambers/valves/great vessel; laterality-gene involvement (ZIC3) links HLHS to the broader left-right patterning disease spectrum in some cases (heterotaxy-associated single ventricle).

8. Temporal Development

Onset

  • Congenital — the structural lesion originates in mid-gestation cardiac development (roughly weeks 5–8 for chamber/valve formation, with progressive hypoplasia through the remainder of gestation in flow-mediated cases).
  • Onset pattern: the anatomic lesion is present from early-to-mid fetal life; clinically, presentation is acute in the newborn period as the ductus arteriosus closes (if not prenatally diagnosed and managed).

Progression

  • Fetal: some cases show clear in-utero progression from milder mid-gestation critical aortic stenosis with a borderline (not yet frankly hypoplastic) left ventricle to fully developed HLHS by term — the rationale for fetal aortic valvuloplasty (Section 12).
  • Neonatal/staged-surgical "disease stages": (1) Stage I — Norwood (or hybrid) procedure in the first days of life; (2) Stage II — bidirectional Glenn/hemi-Fontan, typically 4–6 months; (3) Stage III — Fontan completion, typically age 2–4 years. Each stage represents a distinct physiologic configuration rather than "natural" disease progression, but each carries its own interstage mortality risk and morbidity profile.
  • Progression rate/pattern of the underlying disease: after successful staged palliation, the single-right-ventricle Fontan circulation is a chronic, slowly progressive circulatory failure state — patients are at lifelong risk of Fontan-associated complications with a generally progressive (not stable) natural history over decades, though highly variable individually ("high-performing Fontan" phenotype vs. early failure).
  • Duration: HLHS itself, uncorrected, is rapidly fatal (self-limited only in the sense that death occurs within days); with staged palliation it becomes a chronic, lifelong single-ventricle circulatory condition requiring ongoing surveillance.

Patterns

  • Remission: not applicable in the traditional sense — there is no biological remission; "recovery" is surgical/palliative rather than curative, and heart transplantation is the only route to biventricular-equivalent (donor heart) circulation.
  • Critical periods: (1) the immediate ductal-closure window (first 24–72 hours of life) is the most acute critical period pre-intervention; (2) the interstage period between Stage I (Norwood) and Stage II (Glenn) carries the highest post-surgical mortality risk (interstage I mortality historically ~6.7–16% across series; PMC11277754); (3) mid-gestation (roughly 20–30 weeks) is the proposed intervention window for fetal aortic valvuloplasty in evolving HLHS.

9. Inheritance and Population

Epidemiology

  • Prevalence: HLHS accounts for approximately 3–4% of all congenital heart defects. Finnish national registry data report total and live-birth prevalence of 3.66 and 1.78 per 10,000 births, respectively ([WebSearch summary citing Finnish registry data]). Overall birth prevalence estimates across high-income-country registries typically range from ~1.6–2.6 per 10,000 live births (roughly 1 in 3,800–6,000 live births).
  • Incidence: essentially equivalent to birth prevalence given the condition's congenital, non-acquired nature.

Inheritance pattern

  • Predominantly multifactorial/complex (majority of sporadic cases), with a minority of familial cases showing autosomal dominant inheritance with reduced/incomplete penetrance (notably NOTCH1- and NKX2-5-associated families), and rare autosomal recessive patterns (compound heterozygous NOTCH1, recessive MYH6 in reduced-ejection-fraction HLHS).
  • Penetrance: incomplete in familial forms — unaffected obligate carriers of NOTCH1/NKX2-5 variants are reported, and asymptomatic relatives may show milder left-sided lesions (bicuspid aortic valve, mild LVOTO) rather than full HLHS, consistent with variable expressivity. The murine Ohia model directly demonstrates incomplete penetrance (~26% in double-homozygous SAP130;PCDHA9 mutants), providing a mechanistic parallel for human incomplete penetrance.
  • Expressivity: highly variable — the same causal variant/family can produce phenotypes ranging from isolated bicuspid aortic valve to frank HLHS ("HLHS spectrum" or "LVOTO spectrum" concept).
  • Genetic anticipation: not established/reported for HLHS.
  • Germline mosaicism: plausible given somatic HAND1 mutations detected in cardiac tissue but not blood in some cases; formal germline mosaicism recurrence-risk studies are limited.
  • Founder effects: not specifically described for HLHS.
  • Consanguinity: recessive forms (compound heterozygous NOTCH1, recessive MYH6) are more likely to be identified in consanguineous families, though HLHS is not classically associated with high consanguinity rates the way some AR metabolic disorders are.
  • Carrier frequency: not well established at the population level given genetic heterogeneity; not amenable to a single carrier-frequency estimate.

Population demographics

  • Affected populations: no strong, well-replicated ethnic-specific prevalence differential has been firmly established; some registry data suggest possible variation by ancestry, but results are inconsistent across studies.
  • Geographic distribution: reported prevalence varies modestly across national registries (e.g., Finland ~1.78–3.66/10,000), partly reflecting differences in prenatal diagnosis/termination rates, which substantially affect livebirth prevalence figures across health systems.
  • Sex ratio: HLHS shows a modest male predominance in most series (male:female roughly 1.3–1.5:1), though some analyses report near-equal distribution; sex-stratified US mortality trend data (1999–2024) have been specifically analyzed pre- and post-COVID-19 (Frontiers in Pediatrics 2026, "Sex-stratified trends in hypoplastic left heart syndrome-related mortality among children and young adults in the United States").
  • Age distribution: essentially all cases present prenatally or in the immediate neonatal period; the surviving population age distribution has shifted markedly over recent decades as surgical survival has improved, with growing cohorts now reaching adolescence and young adulthood.

10. Diagnostics

Clinical tests

  • Echocardiography (transthoracic, fetal, and postnatal) — the primary diagnostic modality; demonstrates diminutive/absent mitral and aortic valves, hypoplastic LV, hypoplastic ascending aorta/arch, retrograde arch flow, and ductal-dependent physiology. Fetal echocardiography (typically performed at 18–22 weeks' anatomy scan or dedicated fetal cardiac scan) is now the most common route to diagnosis in settings with routine prenatal screening.
  • Chest X-ray: may show cardiomegaly and pulmonary vascular congestion, non-specific.
  • ECG: right ventricular hypertrophy pattern, non-diagnostic alone.
  • Cardiac catheterization: used selectively pre-Fontan (hemodynamic assessment of pulmonary artery pressures/resistance, collateral vessels) rather than for initial diagnosis.
  • Cardiac MRI: increasingly used for pre-Stage II/III surgical planning and for longitudinal ventricular function/volume assessment in survivors.
  • Newborn pulse oximetry screening (critical congenital heart disease [CCHD] screening) — recommended since 2011 by AAP/AHA as a universal newborn screen; meta-analysis of 13 studies (n=229,421) shows pooled sensitivity 76.5% (95% CI 67.7–83.5) and specificity 99.9% for critical CHD detection overall, with a false-positive rate of ~0.14%. HLHS is specifically highlighted as a lesion that can present with significant cardiovascular compromise with only subtle cyanosis, making pulse-oximetry screening particularly valuable as a safety-net for cases missed on prenatal ultrasound (PMC8424789; PMC4946827).

Genetic testing

  • Chromosomal microarray (CMA) and/or karyotype are recommended in essentially all new HLHS diagnoses to identify Turner syndrome, trisomy 13/18, Jacobsen syndrome (11q deletion), and other CNVs.
  • Gene panel testing for CHD-associated genes (NOTCH1, NKX2-5, GATA4, GATA5, MYH6, TBX1, TBX5, TBX20, etc.) is reasonable, particularly with a positive family history or syndromic features.
  • Whole-exome/whole-genome sequencing is increasingly used in research and select clinical contexts (e.g., trio sequencing), given the demonstrated genetic heterogeneity; yield for a single unifying causal variant remains modest in isolated/sporadic HLHS.
  • FISH for suspected microdeletion syndromes (e.g., 22q11.2, though more classically associated with conotruncal defects than HLHS) may be used when specific syndromic features suggest it.

Clinical criteria / differential diagnosis

Differential diagnosis includes other ductal-dependent systemic-circulation lesions: critical aortic stenosis (without full LV hypoplasia), interrupted aortic arch, critical coarctation of the aorta, and other single-ventricle variants (e.g., unbalanced atrioventricular septal defect, double-outlet right ventricle with mitral atresia). Distinguishing features rest on echocardiographic assessment of mitral/aortic valve patency and LV size/function.

Screening

  • Routine prenatal anatomy ultrasound (18–22 weeks) with referral to fetal echocardiography for suspected four-chamber-view abnormalities is the primary population screening pathway.
  • Universal newborn pulse oximetry CCHD screening serves as a postnatal safety net for prenatally undiagnosed cases.
  • No population-level genetic carrier screening program exists for HLHS given its complex/heterogeneous genetic architecture; genetic counseling is offered on a family-specific basis after diagnosis.

Suggested NCIT/LOINC terms: NCIT:C17004 (Echocardiography), NCIT:C63668 (or relevant fetal echocardiography code), LOINC codes for neonatal pulse oximetry screening, NCIT:C15709 (Genetic Testing), NCIT term for chromosomal microarray analysis.

11. Outcome/Prognosis

Survival and mortality

  • Untreated: essentially uniformly fatal within days to weeks of birth.
  • Staged surgical palliation era: high-volume centers now report >90% hospital survival for the Norwood (Stage I) procedure ([search summary]). Historical cohort data (post-Norwood introduction) report roughly 65% 5-year survival.
  • Interstage mortality (between Stage I and Stage II): reported range 2–16% across published series, with one major single-center study reporting 6.7% interstage-I mortality and 9% stage-II mortality.
  • Long-term/adult survival: longitudinal follow-up of the original staged-reconstruction cohorts shows only ~31% of HLHS patients alive without transplant at age 35 years after Fontan completion (JACC 2025, "Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for HLHS," PMID:40533128).
  • Comparative single-ventricle outcomes: a 2024 multicenter study found HLHS patients had a composite outcome (death, transplant, atrial arrhythmia, or thromboembolism) rate of 7.1 per 100 person-years vs. 2.1 per 100 person-years for other single-right-ventricle physiologies, indicating HLHS carries a distinctly worse prognosis even within the broader single-ventricle population (PMID:39604028).
  • Population mortality trends: US age-adjusted mortality rate for HLHS declined significantly 1999–2021 in both sexes, reflecting improved surgical/perioperative care, though a more recent 2026 analysis specifically examines pre- vs. post-COVID-19 sex-stratified trends (Frontiers in Pediatrics 2026).
  • Fetal prognosis: outcome depends heavily on presence/absence of a restrictive atrial septum, ventricular function, and associated anomalies; a restrictive/intact atrial septum in fetal HLHS is a major adverse prognostic factor requiring urgent postnatal intervention (PMID:39625114, "Fetal hypoplastic left heart syndrome: key factors shaping prognosis").
  • Heart transplant waitlist: infants/children with HLHS awaiting transplant have among the highest waitlist mortality of any solid-organ transplant population (~17% in some cohorts).

Morbidity and function

  • Neurodevelopmental outcomes: remain a major concern despite improved survival; in one hybrid-procedure cohort only 10% showed mild developmental delay in at least one domain at 2–3 years (Bayley-III), but broader literature emphasizes persistent, only slightly improved, neurodevelopmental and intellectual impairment across the HLHS survivor population overall (PMC6514277).
  • Fontan-associated complications (late morbidity): protein-losing enteropathy, plastic bronchitis, Fontan-associated liver disease/cirrhosis, atrial arrhythmias, thromboembolism, exercise intolerance, and eventual Fontan circulatory failure requiring heart transplantation in a subset.
  • Quality of life: significantly reduced relative to healthy peers and to children with other chronic illnesses, worsening across school-age years, closely tied to neurodevelopmental status (Section 3).

Prognostic factors

  • Anatomic subtype (mitral/aortic atresia vs. stenosis variants), presence and severity of restrictive/intact atrial septum, right ventricular function, tricuspid valve competence, presence of additional cardiac or extracardiac anomalies, genetic/syndromic status (e.g., MYH6 variant carriers show reduced transplant-free survival), center surgical volume/experience, and choice of Stage I strategy (Norwood with modified Blalock-Taussig-Thomas shunt vs. Sano right-ventricle-to-pulmonary-artery conduit vs. hybrid approach) all influence outcome.
  • Fetal prognostic factors specifically include atrial septal restriction, ventricular function/EFE burden, and coronary flow pattern.

12. Treatment

Immediate medical stabilization (pre-surgical)

  • Prostaglandin E1 (alprostadil) infusion to maintain ductal patency — cornerstone of stabilization pending surgery. NCIT term: relevant to Pharmacotherapy (NCIT:C15986); therapeutic agent alprostadil (CHEBI term for alprostadil).
  • Balanced circulation management: avoidance of excess supplemental oxygen/hyperventilation (which lowers pulmonary vascular resistance and can "steal" flow from systemic circulation), sometimes with controlled hypoventilation or subambient FiO2/added CO2 to balance pulmonary:systemic flow ratio (Qp:Qs).
  • Inotropic/vasoactive support and correction of metabolic acidosis as needed.
  • Atrial septostomy (balloon or blade, catheter-based) if the interatrial communication is restrictive.

Surgical/interventional — staged single-ventricle palliation

  1. Stage I — Norwood procedure (first days of life): reconstruction of a "neoaorta" from the native pulmonary artery and hypoplastic aorta, atrial septectomy, and a source of pulmonary blood flow (modified Blalock-Taussig-Thomas shunt or Sano right-ventricle-to-pulmonary-artery conduit).
  2. Hybrid Stage I (alternative to Norwood in select high-risk patients): bilateral pulmonary artery banding plus ductal stenting plus atrial septostomy (avoids cardiopulmonary bypass in the newborn period). Comparative meta-analysis shows hybrid patients have higher interstage and 1-year mortality than Norwood patients overall but lower mortality specifically in high-risk neonates, with no difference in 3- and 5-year mortality; hybrid patients require more unplanned interventions and longer stage-I hospitalization (PMC11277754).
  3. Stage II — bidirectional Glenn (or hemi-Fontan) (typically 4–6 months of age): superior vena cava anastomosed to the pulmonary artery, reducing right ventricular volume load.
  4. Stage III — Fontan completion (typically 2–4 years of age): inferior vena cava flow routed directly to the pulmonary arteries (lateral tunnel or extracardiac conduit), completing separation of systemic and pulmonary circulations with the single right ventricle supporting only systemic output.

NCIT terms: NCIT:C15329 (Surgical Procedure), NCIT:C16186 (Orthopedic Surgical Procedure — not applicable here; use general cardiac surgical procedure term), specific Norwood/Fontan/Glenn procedure NCIT codes where available; therapeutic_modality: SURGERY.

Heart transplantation

Primary or salvage heart transplantation is used for patients with unfavorable single-ventricle anatomy, ventricular dysfunction, or failed staged palliation (including Fontan failure). Infants/children with HLHS awaiting transplant experience among the highest waitlist mortality of any pediatric solid-organ population (~17%); post-transplant outcomes, including in Jacobsen-syndrome-associated HLHS, have been specifically studied (PMC9864704). NCIT:C15289 (Organ Transplantation); therapeutic_modality: CELL_THERAPY is not correct here — this is an organ transplant, best captured as SURGERY or a dedicated transplantation category if the schema supports it.

Fetal intervention

Fetal aortic valvuloplasty (FAV) — percutaneous, ultrasound-guided balloon dilation of the stenotic fetal aortic valve performed in mid-gestation (typically ~20–30 weeks) for evolving HLHS with growth-restricted but not yet fully atretic left heart structures, aiming to preserve biventricular circulation potential. - Technical success in 84% of 143 fetuses, with 8% fetal demise as a procedural risk (PMID:25052401). - Biventricular circulation achieved postnatally in 50% of successfully treated live-born infants vs. only 16% of those with unsuccessful FAV. - Among infants achieving biventricular circulation, freedom from cardiac death was 96±4% at 5 years and 84±12% at 10 years, better than typical HLHS (single-ventricle) outcomes. - Registered trial: ClinicalTrials.gov NCT01736956 ("Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome"). - NCIT therapeutic_modality: SURGERY (fetal cardiac catheter intervention); relevant NCIT procedural term for balloon valvuloplasty.

Pharmacotherapy (chronic/adjunctive)

  • Diuretics (furosemide, spironolactone) for volume management
  • Afterload reduction / ACE inhibitors in select single-ventricle patients
  • Digoxin in some centers for interstage monitoring/heart-failure management
  • Anticoagulation/antiplatelet therapy (aspirin post-shunt; warfarin or DOACs post-Fontan for thromboprophylaxis)
  • Pulmonary vasodilators (e.g., sildenafil) investigated/used in some Fontan patients to improve exercise tolerance and pulmonary blood flow

Supportive/rehabilitative care

  • Interstage home-monitoring programs (weight, oxygen saturation surveillance) to reduce interstage mortality
  • Nutritional support (often including tube feeding) given high metabolic demand and feeding difficulty
  • Neurodevelopmental surveillance and early-intervention/rehabilitative therapy (physical, occupational, speech) given the elevated risk of developmental delay
  • Psychosocial/family support given documented HRQOL and family-functioning impacts (Section 3)

Experimental therapies

  • Regenerative/cell-based approaches (e.g., autologous cardiac-derived or umbilical-cord-derived stem cell injection at time of staged surgery) have been investigated in early-phase trials for single-ventricle patients, with mixed results to date.
  • Ongoing genetic and iPSC-based mechanistic research (Section 6, 15) is oriented toward eventually identifying molecularly targeted or risk-stratifying approaches, but no approved targeted pharmacotherapy currently exists for the underlying developmental defect.

Treatment outcomes / algorithms

Treatment follows an established staged-palliation algorithm (fetal diagnosis → prenatal counseling ± fetal intervention if eligible → prostaglandin stabilization at birth → Stage I Norwood/hybrid → interstage surveillance → Stage II Glenn → Stage III Fontan → lifelong single-ventricle surveillance → transplant if/when the Fontan circulation fails), individualized by center protocol and patient-specific anatomic/physiologic risk factors.

13. Prevention

Primary prevention

No specific primary prevention exists for HLHS given its complex, largely non-modifiable genetic/developmental etiology. General CHD-risk-reduction measures (optimization of maternal pregestational diabetes control, periconceptional folic acid/multivitamin supplementation, avoidance of known teratogens, maternal weight optimization) are reasonable extrapolated public-health measures, though HLHS-specific preventive efficacy data are lacking.

Secondary prevention (early detection)

  • Routine prenatal anatomy ultrasound with fetal echocardiography referral for suspected four-chamber-view abnormalities — the principal secondary-prevention strategy, enabling delivery-planning at a cardiac surgical center and immediate postnatal prostaglandin stabilization (preventing the catastrophic circulatory collapse that occurs with undiagnosed ductal closure).
  • Universal newborn pulse-oximetry CCHD screening as a postnatal safety net (Section 10).
  • Fetal aortic valvuloplasty as a secondary-prevention-like intervention aimed at halting progression from evolving/borderline left heart hypoplasia to frank HLHS (Section 12).

Tertiary prevention (preventing complications in affected individuals)

  • Interstage home-monitoring programs specifically designed to reduce interstage mortality between Stage I and Stage II palliation.
  • Structured post-Fontan surveillance (echocardiography, cardiac MRI, liver imaging/elastography, protein-losing-enteropathy and plastic-bronchitis surveillance) to detect and manage late Fontan-circulation complications early.
  • Thromboprophylaxis post-Fontan to reduce thromboembolic complications.
  • Neurodevelopmental screening/early intervention programs to mitigate long-term developmental and quality-of-life impact.

Genetic counseling

Offered to families after an HLHS diagnosis to discuss recurrence risk (elevated above general population risk given the complex-genetic/oligogenic architecture, particularly with identified familial variants such as NOTCH1/NKX2-5), the value of chromosomal microarray/karyotype and gene-panel testing, and reproductive options for future pregnancies (including consideration of fetal echocardiographic surveillance in subsequent pregnancies).

Public health

Given HLHS's outsized contribution to infant CHD mortality, public-health emphasis centers on: (1) ensuring access to prenatal anatomy ultrasound/fetal echocardiography, (2) universal newborn pulse-oximetry screening implementation, and (3) regionalization of care to high-volume surgical centers, all of which have measurably improved population-level survival trends over the past two decades.

14. Other Species / Natural Disease

Naturally occurring HLHS as seen in humans is not well documented as a spontaneous veterinary disease entity in the same form; most animal knowledge of HLHS-like pathology derives from engineered/induced genetic models rather than naturally occurring veterinary cases (unlike, e.g., some inherited cardiomyopathies that occur naturally in cats and dogs). Congenital left-heart obstructive lesions (e.g., subvalvular aortic stenosis) do occur naturally in certain dog breeds (e.g., Newfoundlands, Golden Retrievers) and are cataloged in OMIA (Online Mendelian Inheritance in Animals), but these represent a related-but-distinct phenotype (isolated aortic stenosis without the full LV/mitral/aortic-arch hypoplasia complex defining HLHS) rather than a direct naturally occurring HLHS analog.

Comparative/orthologous genes: mouse Nkx2-5, Notch1, Gja1, Hand1, Myh6, Sap130, and Pcdha9 are the principal orthologs used in engineered models (Section 15); NCBI Gene orthology mapping is straightforward for each given high mammalian conservation of these developmental genes.

Zoonotic potential / transmission: not applicable — HLHS is a non-communicable congenital developmental disorder.

15. Model Organisms

Mouse models

  • Ohia mouse line — the flagship genetic mouse model, identified through an ENU forward-genetic mutagenesis screen of ~3,000 mice for cardiac laterality/structural defects. Carries compound heterozygous/digenic mutations in Sap130 and Pcdha9; double-homozygous mutants show HLHS-like phenotype with ~26% penetrance — directly demonstrating incomplete penetrance and a digenic/two-locus requirement paralleling the oligogenic model proposed for human HLHS (In Vivo and In Vitro Approaches to Modeling HLHS, PMC11538128; related CRISPR/Cas9-edited SAP130/PCDHA9 double-mutant studies).
  • Gene-specific phenotype dissection: Sap130 mutation drives the left ventricular hypoplasia component; Pcdha9 mutation drives the aortic/aortic-valve component — an elegant demonstration that combining two distinct developmental lesions reproduces the full HLHS phenotype.
  • Cellular phenotype: increased cardiomyocyte apoptosis, decreased cardiomyocyte proliferation, altered mitochondrial maturation.
  • Physiological recapitulation: a related mouse model paper specifically demonstrates left heart hypoplasia and retrograde aortic arch flow, directly recapitulating the classic human fetal echocardiographic finding (PMC8592017, "A mouse model of hypoplastic left heart syndrome demonstrating left heart hypoplasia and retrograde aortic arch flow").
  • Placental phenotype: the Ohia line also shows placental and fetal abnormalities that recapitulate human HLHS outcomes, though this raises a model-fidelity caveat — placental abnormalities could themselves contribute to (or confound) the cardiac phenotype and may relate to the embryonic lethality seen in some homozygous double mutants, limiting direct translational inference to human HLHS pathogenesis versus a placental-mediated secondary effect.
  • Endocardial fibroelastosis animal model: distention of the immature left ventricle has been shown to trigger EFE development, providing an induced (non-genetic, mechanical) model supporting the flow/hemodynamic theory and reproducing key morphopathological features of evolving fetal HLHS (PMC4433646).

iPSC / in vitro models

  • NOTCH1-null and hypomorphic human iPSC-cardiomyocyte (hiPSC-CM) models: NOTCH1 deficiency downregulates cardiac proliferative gene programs, producing stunted hiPSC-CM proliferation in vitro; hypomorphic (rather than complete null) NOTCH1 expression specifically alters cardiomyocyte cellular architecture, a 2024/2025 bioRxiv study directly relevant to the partial-loss-of-function genetic architecture seen in human HLHS families.
  • MYH6-variant patient-derived iPSC-CMs: iPSC-cardiomyocytes carrying a patient-derived MYH6 head-domain variant show measurably altered contractility, functionally validating the pathogenicity of this variant class (PMC7324479).
  • KMT2D-NOTCH interaction model: implicates KMT2D-NOTCH signaling in coronary artery abnormalities associated with HLHS (bioRxiv 2021).

Zebrafish and cross-species functional screens

  • A 2025 eLife study ("Functional analysis across model systems implicates ribosomal proteins in growth and proliferation defects associated with hypoplastic left heart syndrome") integrates zebrafish, mouse, and human iPSC systems to functionally validate ribosomal-protein candidate genes affecting cardiac growth/proliferation, illustrating the current cross-species functional-genomics approach to HLHS candidate gene validation.

Model characteristics and limitations

  • Phenotype recapitulation: the Ohia mouse and mechanical LV-distention models each capture specific facets of human HLHS (structural digenic hypoplasia; EFE formation via flow disturbance, respectively), but no single current model fully recapitulates the entire human phenotype (genetic heterogeneity + flow-mediated growth arrest + EFE + postnatal ductal-dependent physiology) simultaneously.
  • Limitations: placental confounding in the Ohia line; iPSC-CM models capture cell-autonomous proliferation/contractility defects but cannot model in-vivo hemodynamic/flow contributions or the full 3D valve/chamber morphogenetic process; most models address either the genetic or the hemodynamic arm of pathogenesis rather than their interaction.
  • Applications: candidate gene validation (functional confirmation of exome-sequencing hits), mechanistic dissection of EndMT/EFE formation, drug/therapeutic screening in iPSC-CM platforms, and testing of the combined genetic-plus-hemodynamic ("two-hit") pathogenesis model.

Resources

Model organism databases relevant to HLHS research: MGI (Mouse Genome Informatics, for Ohia/Sap130/Pcdha9/Notch1/Nkx2-5/Gja1/Hand1/Myh6 alleles), IMPC/KOMP (systematic mouse knockout phenotyping), ZFIN (zebrafish orthologs), and patient-derived iPSC repositories (e.g., through the Pediatric Cardiac Genomics Consortium biobank).

Suggested NCBITaxon/model terms: NCBITaxon:10090 (Mus musculus), NCBITaxon:7955 (Danio rerio); relevant MGI allele IDs for the Ohia Sap130/Pcdha9 compound mutant.

Summary of Key Ontology Term Suggestions

Category Suggested terms
Disease MONDO:0004933, OMIM:241550/614435, ORPHA:2248
Phenotypes (HP) HP:0011623 (mitral atresia), HP:0011541 (aortic valve atresia), HP:0031624 (hypoplastic left heart), HP:0005107 (aortic hypoplasia), HP:0001631 (ASD), HP:0001643 (PDA), HP:0000961 (cyanosis)
Genes (HGNC) hgnc:7876 (NKX2-5), hgnc:7881 (NOTCH1), hgnc:4274 (GJA1), hgnc:4811 (HAND1), hgnc:7576 (MYH6), hgnc:12873 (ZIC3)
Biological processes (GO) GO:0007219 (Notch signaling), GO:0003231 (cardiac ventricle development), GO:0003170 (heart valve development), GO:0001837 (EMT), GO:0006915 (apoptosis)
Cell types (CL) CL:0000746 (cardiomyocyte), CL:0000115 (endothelial cell), CL:0000057 (fibroblast)
Anatomy (UBERON) UBERON:0002094 (left ventricle), UBERON:0001917 (mitral valve), UBERON:0002137 (aortic valve), UBERON:0001496 (ascending aorta)
Treatments (NCIT) NCIT:C15986 (Pharmacotherapy — alprostadil), NCIT:C15329 (Surgical Procedure — Norwood/Glenn/Fontan), NCIT:C15289 (Organ Transplantation)

Notes on Evidence Gaps

  • HLHS-specific environmental epidemiology (Section 5) is sparse relative to genetic literature; most environmental claims are extrapolated from the broader CHD/LVOTO spectrum and should be flagged as lower-confidence if curated.
  • Population-level GWAS/common-variant data specific to HLHS are limited; the genetic architecture literature is dominated by rare-variant/exome-sequencing case-cohort studies rather than large-scale GWAS.
  • No naturally occurring veterinary HLHS analog is well established; animal-model evidence is entirely from engineered/induced systems (Section 14–15), which curators should note as a MODEL_SYSTEM evidence-source classification.
  • Direct gene-environment interaction studies specific to HLHS were not identified in this search; the "two-hit" genetic-plus-hemodynamic model remains largely conceptual/inferential rather than directly demonstrated in a single unified human dataset, though the Ohia mouse digenic model provides a genetic-locus parallel.

Sources: - Hypoplastic Left Heart Syndrome - StatPearls - NCBI Bookshelf - Hypoplastic left heart syndrome—a scoping review (PMID:40386366) - OMIM 241550 - HYPOPLASTIC LEFT HEART SYNDROME 1 - OMIM 614435 - HYPOPLASTIC LEFT HEART SYNDROME 2 - Orphanet: Hypoplastic left heart syndrome (ORPHA:2248) - Hypoplastic Left Heart Syndrome Sequencing Reveals a Novel NOTCH1 Mutation (PMID:28608148) - Considering the Genetic Architecture of Hypoplastic Left Heart Syndrome - PMC - Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis - Frontiers: Sex-stratified trends in HLHS-related mortality 1999–2024 - Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for HLHS (JACC, PMID:40533128) - Risk factors for mortality in patients with HLHS after the Norwood procedure - PMC - Fetal hypoplastic left heart syndrome: key factors shaping prognosis (PMID:39625114) - Cardiovascular Outcomes Associated With HLHS Versus Other Single Right Ventricle (PMID:39604028) - Is There a Unified Etiology of HLHS? (PMID:42200818) - Distention of the Immature Left Ventricle Triggers EFE - PMC - Jacobsen Syndrome with HLHS: Outcome after Cardiac Transplantation - PMC - A Rare Combination of Chromosomal Abnormalities in an Infant With Turner Syndrome and HLHS - PMC - Fetal aortic valvuloplasty for evolving HLHS: postnatal outcomes of the first 100 patients (PMID:25052401) - Fetal Intervention for Aortic Stenosis and Evolving HLHS - ClinicalTrials.gov NCT01736956 - A mouse model of HLHS demonstrating left heart hypoplasia and retrograde aortic arch flow - PMC - In Vivo and In Vitro Approaches to Modeling HLHS - PMC - Functional analysis across model systems implicates ribosomal proteins in growth and proliferation defects associated with HLHS - eLife - The Genetic Landscape of Hypoplastic Left Heart Syndrome (PMID:29569026) - Comparison of Morbidity and Mortality Outcomes between Hybrid Palliation and Norwood Palliation Procedures - PMC - Neurodevelopmental outcome in HLHS after hybrid procedure - PMC - Impact of MYH6 variants in hypoplastic left heart syndrome - PMC - Recessive MYH6 Mutations in Hypoplastic Left Heart With Reduced Ejection Fraction (PMID:26085007) - MYH6 Variants Are Associated with Atrial Dysfunction in Neonates with HLHS - PMC - Contractility of iPSC-Cardiomyocytes With an MYH6 Head Domain Variant Associated With HLHS - PMC - Newborn pulse oximetry screening for critical congenital heart defects - PMC - Pulse oximetry screening: a review of diagnosing critical congenital heart disease in newborns - PMC - Children with hypoplastic left heart syndrome have lower quality of life than healthy controls (PMID:28847316) - Hypoplastic Left Heart Syndrome Across the Lifespan - Canadian Journal of Cardiology